# BIO-GENE TECHNOLOGY LIMITED – 2026 ANNUAL REPORT

**Melbourne, Australia: Bio-Gene Technology Limited (ASX:BGT or 'Bio-Gene' or 'the Company')**, is pleased to release its Final Report for the year ended 30 June 2026.

Please find attached the following documents:

- ASX – Appendix 4E Final Report
- 2026 Annual Report

The Annual Report is available on the Company's website:
http://bio-gene.com.au/investor-relations/financial-reports

All highlights and full financial results are contained in the Annual Report.

Approved for release on ASX by Bio-Gene Board of Directors.

**- ENDS -**

**For further information, please contact:**

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

## About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and demand for natural insecticides. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health, animal health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.

For personal use only

For personal use only

**Appendix 4E**
**Final Report**

**BIO-GENE TECHNOLOGY LIMITED**
**ABN 32 071 735 950**

**Details of the reporting period and the previous corresponding period**

| | |
|---|---|
| Full year ended ("current reporting period") | **30 June 2026** |
| Full year ended ("previous corresponding Period") | 30 June 2025 |

**Results for announcement to the market**

| **Key information** | **2026 $** | **2025 $** | **% Change** Up / (Down) |
|---|---|---|---|
| Revenue from ordinary activities | - | - | - |
| Loss from ordinary activities after tax attributable to members | (2,330,805) | (2,584,468) | (9.8%) |
| Loss attributable to members | (2,330,805) | (2,584,468) | (9.8%) |

| **Dividends Paid and Proposed** | **Amount per security** | **Franked amount per security** |
|---|---|---|
| Final dividend | Nil | Nil |
| Interim dividend | Nil | Nil |
| Previous corresponding period | Nil | Nil |

| | |
|---|---|
| Record date for determining entitlements to the dividend. | No dividend has been declared or paid |
| Dividend re-investment plan. | No dividend re-investment plan in operation |

| **Net Tangible Assets Backing** | **2026** | **2025** |
|---|---|---|
| Net tangible asset backing per ordinary security | 0.5 cents | 0.5 cents |

**Control gained or lost over entities in the year**

There were no entities where control was gained or lost during the period.

**Commentary on the Results for the period**

Refer to the commentary on the results for the period contained in the "Review of Operations" included within the Directors' report.

**Status of Audit**

The 30 June 2026 financial report and accompanying notes for Bio-Gene Technology Limited have been audited and are not subject to any disputes or qualifications. Refer to the 30 June 2026 Annual Report for a copy of the auditor's report.

For personal use only

BIO-GENE TECHNOLOGY LTD

# 2026 ANNUAL REPORT



For personal use only

For personal use only


## WHO WE ARE

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides that address the global challenges of food security and public health, whilst dealing with the increasing concerns over insecticide resistance and toxicity of insecticides. Our novel technology is based on naturally occurring beta-triketone compounds, a category of chemistry that offers new solutions for insect management in crop protection (including grain storage), public health, consumer applications and animal health.

Approximately 600 insect types, and other arthropod pests such as ticks and mites, are resistant to more than one insecticide class[1]. Over 60 countries have reported mosquito resistance to at least one insecticide class[2]. The problem of insecticide resistance is expected to increase, with insect-borne diseases such as Malaria, Zika and Dengue fever becoming more widespread and only limited solutions available to address this expansion.

The global insecticide market is valued at over US$31 billion per annum. Our research indicates that the future use of Bio-Gene's new insecticidal active compounds currently in development have the potential to provide significant benefits to society and the environment. The objective is to develop effective insecticides derived from nature that are safe, have low environmental impact and are cost effective to use.

Flavocide® and Qcide® are our lead insecticidal compounds and were developed from the leaf biomass produced by a selected sub-type of *Eucalyptus.* Flavocide contains flavesone, which is a chemically synthesised compound that is identical to the natural version. Our research has indicated flavesone has a unique mode of action that is different to all other currently available insecticides. We have demonstrated flavesone's efficacy against resistant populations of certain pests, thus validating its novel mode of action. Qcide contains high levels of tasmanone and is a natural oil extract from a cultivar of *Eucalyptus cloeziana.* Flavocide and Qcide can be used alone, or in combination with other existing insecticides, where in some cases synergy has been observed.




Our business model involves developing and owning active ingredient registrations internationally, developing proprietary manufacturing and production knowhow and working with strong commercial partners on product development, marketing, distribution and sales. We also enter into commercial development and licensing agreements with commercial partners with complementary capabilities in each of our target markets. Through these partnership arrangements we plan to generate multiple revenue streams from the supply of these active compounds, technology licensing fees, milestone payments, and royalties on product sales.

[1] Sparks & Nauan, 2015: *IRAC: Mode of action classification and insecticide resistance management*
[2] World Health Organisation, 2016: *WHO welcomes new initiative to combat insecticide resistance*

For personal use only

## CHAIR AND CEO'S REPORT

Dear Shareholders,

The 2026 financial year marked an important period of progress for Bio-Gene as we advanced the development and commercialisation of our two proprietary insecticidal platforms, Flavocide and Qcide.

Both compounds are derived from nature and have novel modes of action, providing an important point of differentiation as resistance continues to reduce the effectiveness of conventional insecticides and demand grows for safer and more sustainable pest management solutions.

A major focus during the year was advancing the regulatory-enabling development program for Flavocide. Key acute neurotoxicity and reproductive toxicity studies are now underway, with preliminary reports expected in September 2026. These studies represent important components of the data package that will be included in our application to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for registration of Flavocide as a new active constituent. Australia is expected to provide a foundation for subsequent regulatory applications in the United States and other major markets.

We also made encouraging commercial progress with Qcide. Bio-Gene entered into a non-binding term sheet with Sumitomo Corporation and Nakashima Trading Co. Ltd to develop and market Qcide-containing products in Japan, with the parties working towards a potential launch in late calendar 2026. Qcide also received listing by the Organic Materials Review Institute (OMRI) as a botanical pesticide under the USDA National Organic Program, strengthening its positioning in organic agriculture and environmentally focused markets.

The potential applications for our new insecticidally active compounds have also continued to expand. Flavocide and Qcide are being evaluated against disease-carrying mosquitoes in Asia, with initial results expected during the fourth quarter of calendar 2026. Researchers from Purdue University (USA) also reported encouraging Flavocide results against disease-carrying ticks, while our two development programs targeting public health pests and supported by approximately A$3.0 million in US Department of Defense grant funding continued to progress.

We also continued to build Qcide production capacity, completing our 14th and 15th harvests and further refined our production processes for extraction of Qcide oil from biomass. These activities are important as we prepare to support potential future demand from commercial partners.

Bio-Gene's intellectual property position was further strengthened in July 2026 through the grant of a key US patent covering Flavocide in synergistic combination with permethrin and pyrethrin, with protection expected through to 2040. This followed grants during the year of another Flavocide patent for control of resistant pests in Japan and Australia, and entry into national phase of new patents for Qcide as an ovicide and Flavocide for spatial effects on flying insects.

Importantly, the Company secured support for an A$3.275 million capital raising through a placement and underwritten Share Purchase Plan. These funds provide additional capacity to complete the remaining Flavocide safety studies, increase Qcide production and advance product development and commercial partnerships.


We were also pleased to welcome Drew Speedy as Chief Financial Officer and Company Secretary and congratulate our Executive Director Peter May on receiving the Envu Australian Individual Excellence Professional Pest Management Award 2026.

Bio-Gene enters FY27 with several important milestones ahead, including results from the major Flavocide toxicity studies, the submission of our application for approval of use of Flavocide by the Australian regulator, results from the Asian mosquito evaluation program and continued work towards the potential launch of Qcide products in Japan.

The progress achieved during FY26 has strengthened the foundations for the commercialisation of both Flavocide and Qcide. The growing engagement from commercial, scientific and government partners provides further validation of the potential of our technology.

On behalf of the Board, I thank our shareholders for their continued support, as well as our employees, research collaborators and commercial partners for their contribution throughout the year.

Yours sincerely,



**Alex Ding**

**Non-Executive Chair**



**Tim Grogan**

**Managing Director & Chief Executive Officer**

For personal use only

**CONTENTS**


| | |
|---|---|
| Chair and CEO's Report | 3 |
| Directors' Report | 6 |
| Auditor's Independence Declaration | 29 |
| Corporate Governance | 30 |
| Statement of Profit or Loss and Other Comprehensive Income | 31 |
| Statement of Financial Position | 32 |
| Statement of Changes in Equity | 33 |
| Statement of Cash Flows | 34 |
| Notes to the Financial Statements | 35 |
| Declaration by Directors | 58 |
| Independent Auditor's Report | 59 |
| Shareholder Information | 64 |
| Company Particulars | 67 |


For personal use only



The Board of Directors of Bio-Gene Technology Limited ("Bio-Gene" or the "Company") has resolved to submit the following report together with the financial statements of the Company for the year ended 30 June 2026.

## Directors

The following persons were directors of the Company during the financial year:

Mr. Alex Ding (Non-executive Chair)

Mr. Andrew Guthrie (Non-executive Director)

Mr. Chris Ramsey (Non-executive Director)

Mr. Tim Grogan (Managing Director and CEO)

Mr. Peter May (Executive Director, Research and Development)

Details of each director's qualifications and special responsibilities, together with meetings attended, are set forth in other parts of this report.

## Company Secretary

Mr. Drew Speedy (appointed 1 February 2026)

Mr. Edmond Tern (resigned 1 February 2026)

## Principal Activities

The principal activity of the Company is to pursue the development and commercialisation of naturally derived insecticide products.

Bio-Gene's insecticide active ingredients are Flavocide, a synthetically produced nature-identical compound, and Qcide, a natural plant-derived oil with high levels of tasmanone. Research to date indicates insecticidal activity of these products via a novel mode of action with the potential to overcome existing insecticide resistance in pest populations.

Bio-Gene is seeking to commercialise these products via partners as insecticide formulations for use in a range of target markets. We aim to generate multiple revenue streams from technology licensing fees, milestone payments, royalties and sales of active ingredient by securing and owning active ingredient product registrations, developing proprietary manufacturing and production knowhow, and working with strong commercial partners on product development, marketing and distribution.

## Review of Operations

During the 2026 financial year, Bio-Gene progressed from foundational development into more advanced regulatory, product development and commercialisation activities. Key achievements included the advancement of major Flavocide registration-enabling safety studies, expansion of mosquito vector control evaluation into Asia, progress towards the proposed launch of Qcide products in Japan, further optimisation

For personal use only

and scale-up of Qcide production, progress under two United States Department of Defense-funded development programs, and the strengthening of the Company's intellectual property portfolio.

**Flavocide Development**

Bio-Gene made substantial progress during the year towards assembling the data package required to support registration of Flavocide as a new insecticidal active constituent. Following earlier guidance received through the Australian Pesticides and Veterinary Medicines Authority's pre-application process, the Company advanced a suite of Good Laboratory Practice safety studies intended to support an initial Australian application and subsequent applications in other major jurisdictions.

Results from a completed 28-day repeat-dose oral toxicity study in rats conducted in accordance with OECD Test Guideline 407 and a pilot in-vivo metabolism and pharmacokinetics study conducted under the first part of OECD Test Guideline 417 supported progression into major acute neurotoxicity and reproductive toxicity studies.

The acute neurotoxicity study conducted under OECD Test Guideline 424 is designed to assess whether oral exposure to Flavocide affects neurological health in adult rats, including potential changes in neuro-behaviour and neuropathology. The extended one-generation reproductive toxicity study conducted under OECD Test Guideline 443 is evaluating potential reproductive and developmental effects following prenatal and postnatal exposure to Flavocide, as well as systemic toxicity in parental animals and their offspring. Both studies are being undertaken by contract research organisations in accordance with Good Laboratory Practice standards, making the data suitable for use in countries participating in the OECD Mutual Acceptance of Data framework.

As at the end of the financial year, preliminary reports for both the OECD 424 and OECD 443 studies were expected in September 2026. The preliminary report for the OECD 424 study had originally been expected in May 2026 but was delayed by a software system error affecting one component of the study, which required the system to be updated and validated before the study could continue. The delay is not expected to affect the timing of the Company's initial regulatory submission.

Bio-Gene also planned to progress the remaining core studies required for the Flavocide regulatory dossier on concurrent and overlapping timelines. These include a 90-day repeat-dose oral toxicity study in rats under OECD Test Guideline 408, the Good Laboratory Practice in-vivo metabolism and pharmacokinetics component of OECD Test Guideline 417 and a prenatal developmental toxicity study in rabbits under OECD 414.

In parallel, Bio-Gene progressed a five-batch analysis of Flavocide technical material to characterise product composition and the impurity profile. The Company also planned an accelerated Good Laboratory Practice storage stability study and an ambient real-time storage stability study to confirm the long-term stability of the technical material. These chemistry and stability activities will support the Australian regulatory dossier and future applications in other jurisdictions.

Based on progress during the year, Bio-Gene is targeting Q2 CY2027 for submission of its first application to the Australian Pesticides and Veterinary Medicines Authority for registration of Flavocide as a new active constituent. The initial application is intended to support subsequent product approvals for professional and domestic uses, including public health use patterns for mosquito control and potentially other flying insects. Formulated product registrations would be pursued separately by Bio-Gene's commercial partners. The targeted submission timing remains subject to factors including the availability of study slots, achievement of planned study dates, quality assurance release and the finalisation of study reports

Bio-Gene and its commercial partners continued to invest in formulations of Flavocide suited to target applications in public health, consumer pest control, agriculture and animal health. The Company's earlier pilot-scale manufacturing work with Rallis India on Flavocide, established a scalable synthesis process with material of a consistent technical material specification and provides a pathway to support future registration, product development and commercial supply requirements.

For personal use only

During the year, the US has experienced a very concerning increase in the number of humans infected with tick-related diseases and researchers from Purdue University presented promising new efficacy data for Flavocide against *Ixodes scapularis* ticks at the 17th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Chicago. In laboratory studies, Flavocide formulated as a prototype emulsion-in-water formulation achieved greater than 90% mortality of tick nymphs within 24 hours of exposure, with residual activity observed for up to four weeks under controlled conditions. The researchers proposed further field validation and behavioural studies as part of a product development program.

**Qcide Development**

Bio-Gene continued to advance Qcide production, market access and product development during the year. In December 2025, Qcide was approved by the United States-based Organic Materials Review Institute (OMRI) for listing as a botanical pesticide under the United States Department of Agriculture National Organic Program. Qcide was accepted as a 100% natural, non-synthetic botanical pesticide, with no restrictions applied to its composition or purity.

The listing confirms that Qcide meets relevant United States organic standards and may be used in certified organic production systems, subject to applicable regulatory approvals and standard organic pest-management requirements. While the listing is not itself a product registration or organic certification, it enables the use of the OMRI Listed seal once regulatory approvals are in place and supports potential applications across organic agriculture, crop protection and environmentally focused consumer products. It also establishes a precedent for future listings of formulated products containing Qcide.

The Company completed its 14th Qcide harvest in July 2025 and its 15th harvest in February 2026 at the plantation in Far North Queensland. These harvests further validated production under standardised operating and processing conditions, with Qcide oil produced to a consistent commercial specification.

Bio-Gene continued to optimise the pre-treatment of harvested biomass and modify the steam-distillation process to improve oil recovery from each tonne of biomass and reduce unit production costs as the program moves towards larger-scale commercial supply. The Company's tree improvement and selection program was also expanded to produce superior trees for future production growth, including seed collection from a dedicated on-farm seed production area.

Newly planted areas became well established during the year, with the more advanced sections ready for an initial harvest in spring 2026. Preparations for further seedling production were also undertaken to support re-stocking and expansion of the plantation utilising seed from the now established seed production area. These activities are intended to strengthen the Company's capacity to scale Qcide production in response to future partner and market demand.

**Commercial Partnerships and Market Development**

Bio-Gene completed its annual review of the Company's product pipeline and strategic partnering priorities across the public health, consumer and crop protection sectors. The review confirmed that the eight previously identified target products and use patterns remained priorities based on their technical and commercial progress and alignment with the Company's strategy.

Interest from potential new commercial partners, together with data generated through Bio-Gene's development programs, also identified additional prospective applications for Flavocide and Qcide. The Company continued to assess these opportunities, including potential applications for Qcide that may offer shorter market-entry timelines and the potential for earlier revenue generation than applications requiring registration as a new insecticidal active. Bio-Gene also continued confidential formulation development and prototype efficacy testing of both actives with existing and prospective commercial partners across its target markets.

For personal use only

In March 2026, Bio-Gene signed a non-binding term sheet with Sumitomo Corporation and Nakashima Trading Co. Ltd to develop and market a range of insecticide products containing Qcide for use against household nuisance insect pests in Japan. Under the proposed arrangements, Bio-Gene would produce Qcide oil in Queensland for supply to Nakashima through Sumitomo Corporation and license relevant intellectual property for use by the parties in Japan. Sumitomo Corporation would coordinate ordering, trade financing, transportation and approval for importation, while Nakashima would undertake further formulation and efficacy work and be responsible for packaging, promotion and supply through retail and online channels.

Bio-Gene undertook a wide range of activities during the remainder of the financial year to advance the opportunity in Japan, including preparing draft commercial terms, initiating the application process for approval to import and supply Qcide in Japan, preparing prototype formulations and assessing potential packaging options. The parties are targeting a product launch in late calendar 2026, subject to completion of the required commercial, product development and approval activities.

Bio-Gene also expanded its mosquito vector control development program into Asia. Flavocide and Qcide are being evaluated against *Aedes aegypti*, *Aedes albopictus* and *Culex quinquefasciatus*, mosquito species associated with the transmission of diseases including dengue, chikungunya and Zika. Testing is being conducted in accordance with World Health Organization guidelines in Singapore and the wider region, with the initial phase expected to be completed during the fourth quarter of calendar 2026. The program is intended to generate further efficacy data, inform the Company's regional commercialisation strategy and assess the suitability of Flavocide and Qcide as new nature-derived agents for use in Asian vector control programs.

**United States Department of Defense Programs**

Bio-Gene advanced two development projects funded under the United States Department of Defense's Deployed Warfighter Protection program. The projects are supported by approximately A$3.0 million (US$1.86 million) in competitive grant funding over three years and are intended to develop new insect-control solutions capable of protecting military personnel and civilian populations from insect pests and insect-borne disease.

The first program is developing a wearable device incorporating Flavocide to protect against flying insect vectors such as mosquitoes. During the year, the project progressed through device engineering and formulation development in collaboration with GearJump Technologies and United States military and agricultural research institutions. Device prototypes containing Flavocide were developed and initial entomological testing commenced. Early small-cage trials demonstrated evidence of mosquito mortality, providing early validation that the wearable emanator concept was functioning as intended.

The second program is developing a Qcide-based indoor residual treatment for the control of bed bugs, resting houseflies and other indoor insect pests. Preparatory workstreams were established with United States research partners to support laboratory testing of prototype formulations, with initial studies focused on houseflies. In addition to their potential defence applications, both programs are designed to generate technical and performance data relevant to broader public health and consumer markets.

**Patent and Intellectual Property Protection**

Bio-Gene continued to strengthen its intellectual property portfolio during the year. In June 2026, the Company received a grant from the United States Patent and Trademark Office for a patent covering the use of flavesone, the active compound in Flavocide, in synergistic combination with the established insecticidal actives permethrin and pyrethrin. This patent provides exclusivity in the United States until 2040. Equivalent patents covering these and other important insecticide combinations have been granted in Australia, Japan and New Zealand, and across 22 member states of the African Regional Intellectual Property Organisation, with related applications remaining under examination in additional jurisdictions.

Synergistic combinations are intended to produce a greater insecticidal effect than the individual active ingredients and may enable improved efficacy and differentiated pest control products. The allowance therefore strengthens the commercial potential of Flavocide combination products and creates further

For personal use only

opportunities for licensing and product development with partners across crop protection, public health and consumer markets.

Progress was also made in other patent families with patents granted in Japan and Australia for Flavocide control of resistant pests and entry into national phase (Australia, Brazil, Canada, Europe, India, Japan, New Zealand and the USA) for new patents covering the use of Qcide as an ovicide and Flavocide for spatial effects on flying insects. These new patents will significantly extend the scope of protection on use of the Company's products.

**Corporate**

In July 2025, Bio-Gene completed the second tranche of a placement and its Share Purchase Plan following shareholder approval. The shares issued during the 2026 financial year raised gross proceeds of A$965,121 before costs and completed the A$2.46 million capital raising conducted between May and July 2025. Shareholders also approved the issue of unlisted options associated with the capital raising.

During the June 2026 quarter, Bio-Gene secured binding commitments for a further capital raising of approximately A$3.275 million through a placement to professional and sophisticated investors and an underwritten Share Purchase Plan. The placement comprised an initial tranche of approximately A$1.906 million issued under the Company's existing capacity and a second tranche of approximately A$0.869 million subject to shareholder approval after year-end. The Share Purchase Plan was underwritten to A$500,000, with applications of A$119,500 received and the remaining shortfall placed under the underwriting arrangements in August 2026, following shareholder approval.

Funds raised are being applied to complete the remaining Flavocide safety studies required for the Company's first Australian regulatory application, increase Qcide production, advance product development and commercial partnering activities, fund strategic projects and provide additional working capital.

In November 2025, Bio-Gene received a cash refund of A$519,502 under the Australian Federal Government's Research and Development Tax Incentive program in respect of eligible research and development expenditure incurred during the 2025 financial year. The funds supported the continued development of Flavocide and Qcide and the Company's working capital requirements.

During the year, Bio-Gene appointed Mr Drew Speedy as Chief Financial Officer and Company Secretary. Mr Speedy is a Certified Practising Accountant and member of the Governance Institute of Australia, with more than 20 years' experience in senior finance and company secretarial roles across ASX-listed and private companies.

In July 2026 Bio-Gene's Executive Director - Research and Development, Mr Peter May, received the Envu Australian Individual Excellence Professional Pest Management Award 2026 in recognition of his service, professionalism and contribution to the Australian commercial pest management industry.

## Financial Summary

The financial results of the Company for the year ended 30 June 2026 are summarised as follows:

**Statement of Financial Position**

- Cash held of $1,939,590 (2025: $1,138,338) at reporting date.
- The Company's policy is to hold its cash and cash equivalent deposits in "A" rated or better deposits.
- The Company's strategy is to outsource product development expenses including manufacturing, regulatory and trial expenses, to specialist, best of breed partner organisations. Therefore, the Company

For personal use only

has not incurred any major capital expenditure for the period and does not intend to incur substantial commitments for capital expenditure in the immediate future.

**Operating Results**

- The Company reported a loss from ordinary activities after income tax of $2,330,805 (2025: $2,584,468).
- Total revenue including other income during the period was $1,078,888 (2025: $524,370).
- Total operating expenses for the period were $3,409,693 (2025: $3,108,838). Research and development costs have been expensed in the year in which they were incurred.
- Basic and diluted net loss per share decreased to 0.75¢ (2025: 1.22¢) due to the increase in the weighted average number of shares on issue.

**Statement of Cash Flows**

The Company's cash outflow from operations over the period was $1,938,705 (2025: $2,542,768).

## Capital Raising

On 18 July 2025, 41,961,784 fully paid ordinary shares were issued under tranche 2 of a share placement which provided $965,121 cash before costs.

On 2 June 2026, 76,240,000 fully paid ordinary shares were issued under a share placement which provided $1,906,000 cash before costs.

On 24 June 2026, 4,780,000 fully paid ordinary shares were issued under a share purchase plan which provided $119,500 cash before costs.

On 30 June 2026 the Company had 386,081,108 shares on issue (2025: 266,419,324). Refer to Note 13(a) for further detail of movements in issued capital.

## Options Issued

The following options were issued during the current financial year as part of the 2025 capital raising:

- 55,035,096 options with an exercise price of 3.4 cents and expiry date of 15 May 2028.
- 55,035,096 options with an exercise price of 4.6 cents and expiry date of 15 May 2030.

Further details in respect of options issued in the current and previous financial years can be found in Note 13(b).

## Earnings Per Share

| | 2026 | 2025 |
|---|---|---|
| Basic loss per share from continuing operations | (0.75¢) | (1.22¢) |
| Basic diluted loss per shares from continuing operations | (0.75¢) | (1.22¢) |

For personal use only

## Dividends

No dividends were paid or declared during the course of the financial year and no dividends are recommended in respect to the financial year ended 30 June 2026.

## Likely Developments and Expected Results of Operations

The Company will continue to fully evaluate Flavocide and Qcide in a range of market applications, and to develop a comprehensive data package to support product registrations in Australia and internationally.

Disclosure of information, in addition to that provided in this report, regarding likely developments in the operations of the Company in future financial years and the expected results of those operations is likely to result in unreasonable prejudice to the Company. Accordingly, this information has not been disclosed in this report.

## Significant Changes in State of Affairs

Other than as detailed in this Annual Report, there were no significant changes to the state of affairs of Bio-Gene Technology Limited during the year.

## Business Strategies and Prospects

The Company's strategy is to develop its proprietary technologies to a point where they can be licensed to commercial partners for further development and ultimately released to the market. Bio-Gene would generate revenue from the supply of the active ingredients, milestone payments and royalty revenues from such transactions.

## Material Business Risks

The Company's operations and business prospects are subject to a number of risks. The Board regularly reviews the possible impact of these risks and seeks to minimise this impact through a commitment to its corporate governance principles and risk management function. However, not all risks are manageable or within the control of the Company. The key business risks faced by the Company that are likely to affect its future prospects include:

### Laboratory and Field Trials

Development of the Company's products may fail for a number of reasons including lack of efficacy, toxicity or adverse side effects. Failure can occur at any stage of the trials, requiring the Company to abandon or repeat trials. The Company or the relevant regulatory authorities may suspend the Company's trials at any time if it appears that the trials could potentially result in unacceptable health risks.

### Manufacturing/production

The Company has successfully manufactured product at a scale sufficient to conduct the trials that have been undertaken to date. The Company is now working on improving the production process to allow for cost effective manufacturing at scale. With any chemical production process, however, there is inherent variability which cannot be controlled and therefore the yields of finished product can vary. The Company's production technologies have also not been tested at a scale sufficient to make commercial quantities of a product in the event that it proves successful and can be brought to market and are therefore subject to risk of failure or high costs.

For personal use only

**Out-licencing**

The Company is relying on its ability to be able to out-licence its products at a time deemed appropriate. The agriculture, consumer, public health and animal health sectors are highly competitive and numerous entities around the world compete with the Company to discover, validate and commercialise insecticides. The Company's competitors may discover and develop products in advance of the Company and/or products that are more effective than those developed by the Company. As a consequence, the Company may not be able to out-licence its products or not be able to out-licence its products for the desired returns, resulting in adverse effects on revenue and profitability.

**Sufficiency of Funding**

The Company has limited financial resources and may need to raise additional funds from time to time to finance the development and commercialisation of its products and its other objectives. The Company's product development activities may never generate revenues, and the Company may never achieve profitability. The Company's ability to raise funds in the future will be subject, among other things, to factors beyond the control of the Company and its Directors including cyclical factors affecting the economy and share markets generally. The Directors can give no assurance that future funds can be raised by the Company on favourable terms, if at all.

**Third Party Collaborations**

The Company has established and intends to continue to establish collaborative relationships to achieve its product development objectives. The Company does not have all the resources that it needs to internally develop its product candidates through to full development and to launch marketable products and relies on its ability to maintain and enter into collaborative and licencing relationships to achieve this objective, and relies on its collaborators to fulfil their responsibilities. Any failure by these collaborators to fulfil their responsibilities could adversely impact the Company.

## Insurance and Indemnification

During the financial year, the Company paid a premium in respect of a contract insuring the Directors and Company Secretary (as named above), and all executive officers of the Company against a liability incurred when acting in their capacity as a Director, Company Secretary or executive officer to the extent permitted by the *Corporations Act 2001*. Further disclosure required under section 300(9) of the *Corporations Act 2001* is prohibited under the terms of the insurance contract.

Other than to the extent permitted by law, the Company has not otherwise, during or since the end of the financial year, indemnified or agreed to indemnify an officer or auditor of the Company or any other related body corporate against a liability incurred as such by an officer or auditor.

## Proceedings on Behalf of the Company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Company with leave of the Court under section 237 of the *Corporations Act 2001*.

For personal use only

## Environmental Issues

The Company's operations are not currently regulated by any significant environmental regulation under a law of the Commonwealth or of a state or territory of Australia.

## Auditor's Independence Declaration

A copy of the auditor's declaration under section 307C of the *Corporations Act 2001* in relation to the audit for the year ended 30 June 2026 is included in this report.

## Auditor

Under s329 (8) of the Corporations Act 2001, and with effect from 9 April 2026, ASIC provided its consent to the resignation of the incumbent auditor and appointment of Horizon Nexus (Audit) Pty Ltd (formerly called MVAB Audit Pty Ltd).

## Non-audit

The Board of Directors has considered the position and is satisfied that the planned provision of the non-audit services is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001* for the following reasons:

- All non-audit services have been reviewed to ensure they do not impact the impartiality and objectivity of the auditor.
- None of the services undermine the general principles relating to auditor independence as set out in Professional Statement APES 110, including reviewing or auditing the auditor's own work, acting in a management or a decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risk and rewards.

During the year the following fees were paid or payable for services provided by the previous auditor of the Company MVAB Bennett, its related practices and non-related audit firms: $8,000. No non-audit fees were paid to Horizon Nexus (Audit) Pty Ltd.

No officers of the Company have at any time been a partner or director of the auditor.

For personal use only

For personal use only

## Meetings of Directors

The number of meetings of the Company's Directors (including committee meetings of Directors) held during the year ended 30 June 2026 and the numbers of meetings attended by each Director were:

| Director | Board of Directors | | Remuneration & Nomination Committee | | Audit & Risk Committee | |
|---|---|---|---|---|---|---|
| | Held and Eligible to Attend | Attended | Held and Eligible to Attend | Attended | Held and Eligible to Attend | Attended |
| Alex Ding | 12 | 12 | 4 | 4 | 2 | 2 |
| Andrew Guthrie | 12 | 12 | 4 | 4 | 2 | 2 |
| Chris Ramsey | 12 | 12 | 4 | 4 | 2 | 2 |
| Tim Grogan | 12 | 12 | - | - | - | - |
| Peter May | 12 | 12 | - | - | - | - |

Information on directors and key management personnel in office during or since the end of the financial year and to the date of this report.

## Information on Directors

| Alex Ding | Non-Executive Chair |
|---|---|
| Experience and qualifications<br><br>BComm, LLB (UNSW)<br>LLM (USyd) | Alex has over 25 years of experience as a corporate lawyer. He was a partner at two leading Australian law firms and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government-controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He had been named on The Best Lawyers in Australia list.<br><br>Alex joined as Non-Executive Director of Bio-Gene Technology Limited on 12 May 2023 and was appointed as Non-Executive Chair of the Board on 1 August 2023. |
| Special Responsibilities | Chair of the Board of Directors and member of the Audit and Risk Committee and Remuneration and Nomination Committee. |
| Interest in Shares and Options | 34,122,081 Fully Paid Ordinary Shares<br><br>10,869,565 Options (exercise price $0.34 expiry 15-May-28)<br><br>10,869,565 Options (exercise price $0.46 expiry 15-May-30) |
| Directorships held in Other Listed Entities | Has not held a directorship in any other listed entity over the last 3 years |

For personal use only

| **Tim Grogan** | **Managing Director and Chief Executive Officer** |
|---|---|
| Experience and qualifications<br><br>Bachelor of Law<br>Bachelor of Science (chemistry) University of Melbourne | Joined as Managing Director and Chief Executive Officer on 28 August 2023. Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors. Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar. Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, a venture capital-funded medicinal drug discovery and development company, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base.<br><br>Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma (ASX:SPL), where he worked to steer it through the IPO process and establishing several commercial relationships globally. |
| Special Responsibilities | Responsible for the management of the Company. |
| Interest in Shares and Options | 476,916 Fully Paid Ordinary Shares<br>100,000 Options (exercise price $0.35 expiry 15-Oct-27)<br>108,696 Options (exercise price $0.34 expiry 15-May-28)<br>108,696 Options (exercise price $0.46 expiry 15-May-30) |
| Directorships held in Other Listed Entities | Has not held a directorship in any other listed entity over the last 3 years |
| **Peter May** | **Executive Director – Research & Development** |
| Experience and qualifications<br><br>Bachelor of App.Sc (Rural Technology) (Hons) University of Queensland<br>MBA Queensland University of Technology<br>GAICD | Director of Bio-Gene Technology Limited since 29 May 2015.<br><br>Peter's career has included over 20 years of experience in the Australian and international crop protection and pest management markets with companies Orica and Crop Care Australasia (now part of Nufarm). In 2001, he founded Xavca Pty Ltd, providing marketing & consultancy services to mainly international clients including Syngenta and Sorex (now part of BASF). In 2008 Peter joined BioProspect Limited (ASX: BPO) as Chief Executive Officer and subsequently was appointed Non-Executive Director and then Non-Executive Chair of that company.<br><br>Peter is a graduate member of the Australian Institute of Company Directors (AICD) and member of the Australian Environmental Pest Managers Association (AEPMA) and the Mosquito Control Association of Australia (MCAA). |
| Special Responsibilities | Responsible for the Research and Development of the Company. |

| | |
|---|---|
| Interest in Shares and Options | 2,259,597 Fully Paid Ordinary Shares<br>100,000 Options (exercise price $0.35 expiry 15-Oct-27)<br>108,696 Options (exercise price $0.34 expiry 15-May-28)<br>108,696 Options (exercise price $0.46 expiry 15-May-30) |
| Directorships held in Other Listed Entities | Has not held a directorship in any other listed entity over the last 3 years |
| **Chris Ramsey** | **Non-Executive Director** |
| Experience and qualifications<br><br>BRuSc UNE Armidale GradDip Agribusiness Monash Uni. | Chris has over 30 years' experience in the agricultural sector across business startup, development, marketing and broader agronomy. He has held leadership roles in Bayer, BASF and Nufarm/Crop Care among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and Zondii, an agtech business that is developing technology for Australian wool producers. He is also the principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness.<br><br>Director of Bio-Gene Technology Limited since 12 May 2023. |
| Special Responsibilities | Chair of the Remuneration and Nomination Committee and member of the Audit and Risk Committee. |
| Interest in Shares and Options | 319,000 Fully Paid Ordinary Shares<br>100,000 Options (exercise price $0.35 expiry 15-Oct-27) |
| Directorships held in Other Listed Entities | Has not held a directorship in any other listed entity over the last 3 years |

For personal use only

For personal use only

| **Andrew Guthrie** | **Non-Executive Director** |
|---|---|
| Experience and qualifications<br><br>B. AgSci (Hons)<br>GAICD | Andrew has dedicated his career to agriculture and worked for 32 years with one of the world's leading agriculture companies, Syngenta, and predecessor companies around the world. After building his early career in sales, marketing and supply chain roles in Australian agriculture, Andrew spent 20 years working internationally with assignments in the United Kingdom, Switzerland, Hong Kong, Singapore, Thailand, Japan and China. He gained significant experience in diverse cultural environments that require broad leadership skills. Andrew spent most of his senior leadership years with Syngenta in Asia, as Regional Director for Asia Pacific, before he was promoted to lead Syngenta's multi-billion-dollar business in Europe, Africa and the Middle East.<br><br>During his career, Andrew led business growth in developed and emerging markets by creating country operating businesses with the right culture, capability, people and business strategies to access attractive market segments that constituted tens of millions of grower customers in some countries. Andrew has a strong understanding of corporate governance and the risk management required to successfully grow business in emerging markets.<br><br>Andrew was a member of Syngenta's Global Crop Protection Leadership team that was responsible for business strategy that leveraged Syngenta's extensive research and development capability to invent, gain regulatory approval and launch new products, including insecticides, to agricultural markets globally. In 2019 he retired from executive management roles and now acts as a company director and mentor.<br><br>Andrew joined as Non-Executive Director of Bio-Gene Technology Limited since 26 April 2021. |
| Special Responsibilities | Chair of the Audit and Risk Committee and member of the Remuneration and Nomination Committee. |
| Interest in Shares and Options | 684,784 Fully Paid Ordinary Shares<br><br>100,000 Options (exercise price $0.35 expiry 15-Oct-27)<br><br>108,696 Options (exercise price $0.34 expiry 15-May-28)<br><br>108,696 Options (exercise price $0.46 expiry 15-May-30) |
| Directorships held in Other Listed Entities | Non-Executive Director of Terragen Holdings Limited |
| **Drew Speedy** | **Chief Financial Officer and Company Secretary** |
| Experience and qualifications<br><br>B.Bus (Accountancy),<br>CPA<br>GAICD | Drew has held numerous Chief Financial Officer and Company Secretary roles across ASX-listed and private companies over the past 20 years. He is the founder and Director of DTS Corporate Pty Ltd, which provides CFO and company secretarial services to ASX-listed and private entities.<br><br>Drew has extensive experience across all aspects of financial reporting, corporate governance, capital raisings, mergers and acquisitions, IPOs and ASX compliance.<br><br>Drew joined Bio-Gene on 1 February 2026. |
| Special Responsibilities | Responsible for the financial management and company secretariate of the Company |

| | |
|---|---|
| Interest in Shares and Options | 600,000 Fully Paid Ordinary Shares<br>300,000 Options (exercise price $0.35 expiry 15-Oct-27) |
| Directorships held in Other Listed Entities | Has not held a directorship in any other listed entity over the last 3 years |

## Remuneration Report

### Introduction

This Remuneration Report for the year ended 30 June 2026 outlines the remuneration arrangements in place for the key management personnel (**KMP**) of Bio-Gene Technology Limited which comprises all Directors (executive and non-executive) and those executives who have authority and responsibility for planning, directing and controlling the activities of the Company.

The remuneration report is set out under the following main headings:

a) Key management personnel
b) Remuneration governance
c) Principles used to determine the nature and amount of remuneration
d) Details of remuneration
e) Service Agreements
f) Share-based compensation to Directors and key management personnel
g) Additional disclosures relating to Directors and key management personnel

### Key management personnel

The following individuals were classified as KMP during the 2026 financial year and unless otherwise indicated were classified as KMP for the entire year.

| | |
|---|---|
| **Non-Executives** | |
| Mr. Alex Ding | Non-Executive Chair |
| Mr. Andrew Guthrie | Non-Executive Director |
| Mr. Chris Ramsey | Non-Executive Director |
| **Executives**<br>with the greatest authority for the strategic direction and management of the group ("other key management personnel") during the financial period | |
| Mr. Tim Grogan | Managing Director and Chief Executive Officer |
| Mr. Peter May | Executive Director Research & Development |
| Mr. Drew Speedy | Chief Financial Officer and Company Secretary (appointed 1 Feb 2026) |
| Mr. Edmond Tern | Chief Financial Officer and Company Secretary (resigned 1 Feb 2026) |

For personal use only

For personal use only

## Remuneration governance

**Role of Remuneration and Nomination Committee (Committee)**

The Company has adopted various Corporate Governance charters and policies including a Remuneration & Nomination Committee Charter. The Charter includes principles for establishing appropriate remuneration policies and levels including incentive policies for directors and senior executives and ensuring that senior executives are being rewarded commensurate with their responsibilities and the market. Further information on the Committee's role and responsibilities is contained in its Charter which is available on the Company's website at https://bio-gene.com.au.

The Committee is Chaired by Chris Ramsey. The other Non-Executive Directors of the Board (Mr. Andrew Guthrie and Mr Alex Ding) are all members of the Committee.

The Committee is authorised by the Board to obtain outside independent professional advice with relevant experience and expertise. No advice as to specific remuneration levels nor actual remuneration recommendations were provided by independent consultants during the year.

The Non-Executive Directors of the Company have previously worked closely with Madison Partners (an independent professional advisory firm specialising in remuneration issues) and have developed the Executive Remuneration Strategy and Structure which is outlined below.

The Committee commenced a review of the remuneration arrangements in the 2026 financial year. The Board believes the Remuneration Strategy and Structure to be appropriate and effective in that it needs to create goal congruence between directors, executives and shareholders.

## Principles used to determine the nature and amount of remuneration

**Executive remuneration strategy and structure**

The Company's remuneration strategy is founded on the objective of aligning remuneration with the interests of the Company's shareholders by providing market competitive remuneration arrangements that attract, incentivise and retain quality personnel and which encourage and promote achievement of the Company's short and medium term strategic objectives consistently with the Company's longer term corporate goals.

The remuneration strategy is underpinned by a remuneration structure comprising fixed remuneration, a short-term incentive and long-term incentive as described below:

**Fixed Remuneration (FR)**

FR consists of base salary and statutory superannuation contributions in recognition of day-to-day accountabilities. KMP and other personnel may elect to have specific benefits provided out of fixed remuneration on a total employment cost basis, that is, the cost of the benefit along with any costs of providing the benefit such as fringe benefits tax are deducted from pre-tax salary.

**Short-Term Incentive (STI)**

The STI is now a cash-based plan that involves linking the achievement of specific financial and non-financial stretch targets using a balanced scorecard approach with the opportunity to earn an annual incentive up to a maximum set percentage of total remuneration.

For personal use only

**Long-Term Incentive (LTI)**

Any LTI plan would be an equity-based plan which is intended to provide the opportunity to earn incentives over the medium and longer term based on the achievement of the Company's strategic goals and the creation of shareholder value measured in terms of share price growth.

Total Remuneration refers to the aggregate of the above remuneration components. Remuneration mix refers to the proportion of Total Remuneration that each remuneration component makes up. The mix of remuneration components within the Company's remuneration structure is as follows:

| Component | Fixed remuneration | Short-term incentive | Long-term incentive |
|---|---|---|---|
| CEO | 50% | 25% | 25% |
| Executive Team | 70% | 15% | 15% |
| Senior Managers | 70% | 15% | 15% |

## Executive remuneration components

**Fixed Remuneration (FR)**

Fixed pay is set with reference to the assessment of the external market for comparable roles having regard to relevant industries and the relative stage of an organisation's business life cycle taking into consideration the size and complexity of the role and the skills and experience of the incumbent.

**Short-Term Incentive (STI)**

Under the STI, executives and other personnel were awarded cash having regard to the short-term incentive proportion of their total remuneration (the STI value) and the extent to which performance has been achieved against stretch targets over the financial year.

Performance is determined by assessing actual performance against targets across a number of financial and non-financial dimensions as described in the table below. The team are measured as a group using these criteria as it is considered key to encouraging a team approach to achieving the Company's objectives.

| Component | Percentage of Scorecard |
|---|---|
| Customers and partners | 40% |
| Intellectual property and technology enabling | 20% |
| Corporate overarching (including funding) | 40% |
| | **100%** |

The STI Value is determined by applying the team's performance out of 100% to the team's maximum potential STI amount. The STI Value (subsequent to assessment and approval) is then delivered immediately in cash.

**Long-Term Incentive (LTI)**

Under the LTI, executives and other personnel will be awarded equity under an equity plan, having regard to the long-term incentive proportion of total remuneration (the LTI value). The LTI value will be satisfied with the issue of equity and this equity will then be tested against specific performance conditions in future years to determine whether the equity vests.

The Company does have an approved Equity Plan in place.

For personal use only

## Performance and remuneration outcomes

The tables below provide a summary of the STI key balanced scorecard objectives and outcomes for the year ended 30 June 2026. The objectives are agreed with the Board at the beginning of each financial year and are designed to focus executives on delivering against agreed priorities.

The Non-Executive Directors conduct an assessment of performance of objectives to determine outcomes based on the measures previously set by the Board

| Component | Percentage of Scorecard | 2026 Outcomes |
|---|---|---|
| Customers and partners | 40% | - |
| Intellectual property and technology enabling | 20% | - |
| Corporate overarching (including funding) | 40% | - |
| | **100%** | **-** |

The table below summarises the remuneration outcomes for executives under the Company's STI and LTI programs having regard to the performance outcomes outlined above.

| 2026 | STI | | | | LTI |
|---|---|---|---|---|---|
| Name | Maximum STI | Actual STI | Max STI Value | Actual STI Payable in Cash | LTI Type 1 Shares Vested |
| | % of TR | % of TR | | | |
| | % | % | $ | $ | Number |
| Tim Grogan | 25 | - | - | - | - |
| Peter May | 15 | - | - | - | - |
| Edmond Tern | 15 | - | - | - | - |

## Non-Executive Director Remuneration

The Company's remuneration strategy regarding non-executive directors is that remuneration for non-executive directors should be sufficiently competitive to attract and retain individuals of calibre that have the skills and experience to contribute towards a Board that will drive the Company towards achievement of shareholder aligned objectives whilst fulfilling its governance role of prudential oversight.

Following on from the establishment of the Remuneration & Nomination and Audit & Risk Committees effective 1 October 2021, additional fees are provided for Chairing a committee ($5,000) and membership of a committee ($2,500) in addition to board fees.

## Details of remuneration

### Year ended 30 June 2026

Details of the remuneration of each Director of Bio-Gene and the key management personnel (KMP) of the Company are set out in the following table for the year ended 30 June 2026. As indicated above incentives are dependent upon the attainment of agreed corporate and individual milestones and all incentives related to the year have been expensed in full over the vesting period.

| 2026 | Short-term employee benefits | | Post employment benefits | | Equity-based payments | | Total |
|---|---|---|---|---|---|---|---|
| Name | Cash salary & fees | Cash STI | Non-monetary benefits | Superannuation | STI | LTI | |
| | $ | $ | $ | $ | $ | $ | $ |
| **Executive Directors** | | | | | | | |
| Peter May | 202,938 | - | - | 24,353 | - | - | 227,291 |
| Tim Grogan | 311,003 | - | - | 37,320 | - | - | 348,323 |
| **Non-Executive Directors** | | | | | | | |
| Alex Ding | 67,298 | - | - | 8,076 | - | - | 75,374 |
| Andrew Guthrie | 53,367 | - | - | 6,404 | - | - | 59,771 |
| Chris Ramsey | 46,429 | - | - | 5,571 | - | - | 52,000 |
| **Total Directors** | **681,035** | **-** | **-** | **81,724** | **-** | **-** | **762,759** |
| **Other KMP** | | | | | | | |
| Drew Speedy(1) | 67,742 | - | - | - | - | - | 67,742 |
| Edmond Tern(2) | 75,425 | - | - | 7,071 | - | - | 82,496 |
| **Total Other KMP** | **143,167** | **-** | **-** | **7,071** | **-** | **-** | **150,238** |
| **Total** | **824,202** | **-** | **-** | **88,795** | **-** | **-** | **912,997** |

(1) Drew Speedy was appointed CFO and Company Secretary on 1 Feb 2026.
(2) Edmond Tern resigned as CFO and Company Secretary on 1 Feb 2026.

| 2025 | Short-term employee benefits | | Post employment benefits | | Equity-based payments | | Total |
|---|---|---|---|---|---|---|---|
| Name | Cash salary & fees | Cash STI | Non-monetary benefits | Superannuation | STI | LTI | |
| | $ | $ | $ | $ | $ | $ | $ |
| **Executive Directors** | | | | | | | |
| Peter May | 203,601 | 16,882 | - | 25,384 | - | - | 245,867 |
| Tim Grogan | 312,336 | 45,274 | - | 41,169 | - | - | 398,779 |
| **Non-Executive Directors** | | | | | | | |
| Alex Ding | 67,591 | - | - | 7,783 | - | - | 75,374 |
| Andrew Guthrie | 53,599 | - | - | 6,172 | - | - | 59,771 |
| Chris Ramsey | 46,631 | - | - | 5,369 | - | - | 52,000 |
| **Total Directors** | **683,758** | **62,156** | **-** | **85,877** | **-** | **-** | **831,791** |
| **Other KMP** | | | | | | | |
| Edmond Tern | 128,183 | - | - | 14,758 | - | - | 142,941 |
| **Total Other KMP** | **128,183** | **-** | **-** | **14,758** | **-** | **-** | **142,941** |
| **Total** | **811,941** | **62,156** | **-** | **100,635** | **-** | **-** | **974,732** |

For personal use only

For personal use only

## Service agreements

| Key Management Personnel | Position held as of 30 June 2026 | Contract Details | Incentive |
|---|---|---|---|
| Alex Ding | Non-Executive Chair | Letter of appointment | Not applicable |
| Andrew Guthrie | Non-Executive Director | Letter of appointment | Not applicable |
| Chris Ramsey | Non-Executive Director | Letter of appointment | Not applicable |
| Tim Grogan | Managing Director and Chief Executive Officer | Permanent employment contract<br>$348,317 per annum<br>Four month's termination notice period | 25% STI<br>25% LTI |
| Peter May | Executive Director - Research & Development | Permanent employment contract<br>Part-time - 0.9 FTE<br>$227,290 per annum<br>Two month's termination notice period | 15% STI<br>15% LTI |
| Drew Speedy | Chief Financial Officer and Company Secretary (appointed 1 Feb 2026) | Consulting agreement<br>Part-time<br>$150,000 per annum (exc GST)<br>Two months' termination notice period | Not applicable |

## Share-based compensation to Directors and key management personnel

**Loan Share Plan (LSP)**

The Company issues equity to Directors, employees and key consultants under the Loan Share Plan (LSP). Under the plan, participants are issued with equity to foster an ownership culture to motivate Directors, employees and consultants to achieve performance targets of the Company. Participation in the plan is at the Board's discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.

The LSP was re-approved at the 2019 Annual General Meeting. Only Australian residents are eligible to participate in the plan. The plan allows non-recourse, interest free loans to be provided to eligible participants to acquire shares under the plan. If and when an issue is made involving an interest free-loan, it is treated as an in-substance grant of options and expensed over the vesting period because of the limited recourse nature of the loans.

Generally, except for shares issued as part of the annual short-term incentive arrangements, shares issued under the plan will vest over a three-year period. The shares are acquired in the name of the participant and each participant authorises and appoints the Company Secretary to act on their behalf. Any dividends paid on the shares are used to repay the loan. In all other respects the shares issued under the LSP carry the same rights as other ordinary shares on issue.

If the participant leaves the Company, any shares that have not vested will be bought back by the Company and cancelled along with the loan. In respect of shares that have vested the loan balance must generally be

paid in full within six months of termination or the shares will be sold and the proceeds applied to settle the loan balance. The issue price of the shares in the Company held under LSP is not included in equity until the loan has been repaid.

In accordance with the rules of the LSP the Board has the ability to vary the terms in respect of issues in circumstances it considers appropriate. The valuations of shares issued under the LSP are determined by using an industry standard pricing model taking into account the terms and conditions upon which the instruments were issued.

Participants are not permitted to enter into transactions which limit the economic risk of participating in the plan other than as described above as the LSP allows participants access to a limited recourse loan to fund the acquisition of any shares issued under the LSP.

The terms and conditions of each issue of equity affecting remuneration of Directors and key management personnel in this or future reporting periods are as follows:

| Issue date | No. of shares | Loan expiry date | Vesting date | Issue price $ | Fair value per share at issue date $ | Date first available to deal with |
|---|---|---|---|---|---|---|
| 30/06/2016 | 96,000 | 30/06/2026 | 30/06/2016 | 0.050 | 0.0334 | 30/06/2016 |
| 11/05/2017 | 312,500 | 11/05/2027 | 11/11/2017 | 0.092 | 0.0622 | 11/11/2017 |
| 11/05/2017 | 312,500 | 11/05/2027 | 11/05/2018 | 0.092 | 0.0622 | 11/05/2018 |
| 26/07/2017 | 187,500 | 26/07/2027 | 26/01/2018 | 0.140 | 0.0922 | 26/01/2018 |
| 26/07/2017 | 187,500 | 26/07/2027 | 26/07/2018 | 0.140 | 0.0894 | 26/07/2018 |
| 04/12/2017 | 500,000 | 04/12/2024 | 04/12/2018 | 0.131 | 0.1314 | 04/12/2018 |
| 04/12/2017 | 500,000 | 04/12/2024 | 04/12/2018 | 0.128 | 0.1275 | 04/12/2018 |
| 01/11/2019 | 2,201,972 | 01/11/2026 | 30/06/2022 | 0.150 | 0.0789 | 30/06/2022 |
| 30/07/2020 | 1,262,930 | 30/07/2027 | 30/06/2023 | 0.134 | 0.0843 | 30/06/2023 |

**Equity Issued to Directors and Key Management Personnel**

Details of equity issued in the Company provided as remuneration to each Director and the key management personnel of the Company are set out below. When vested, prior to the Director or key management personnel being able to deal with each share, the loan advanced to acquire the share under the LSP must be repaid.

The assessed fair value at the date of issue of the equity instruments is allocated over the period from issue date to vesting date, and this amount is included in the remuneration tables above. Fair values at issue date are determined using a binomial option pricing model that takes into account the amount of loan, the term of the loan, the share price at issue date and expected price volatility of the Bio-Gene shares, the expected dividend yield and the risk-free interest rate for the term of the loan.

Further information on the shares issued under the LSP, including factors and assumptions used in determining fair value is set out in Note 13 to the financial statements.

Details of shares that have been issued and vested in this or the previous year are outlined in the table below. The tables only include transactions whilst a person is a member of the key management personnel.

For personal use only

| Name | Shares issued during the year | | | | Shares vested during the year | |
|---|---|---|---|---|---|---|
| | 2026 | | 2025 | | 2026 | 2025 |
| | Number | Loan per share $ | Number | Loan per share $ | Number | Number |
| **Directors** | | | | | | |
| Alex Ding | - | - | - | - | - | - |
| Andrew Guthrie | - | - | - | - | - | - |
| Chris Ramsey | - | - | - | - | - | - |
| Peter May | - | - | - | - | - | - |
| Tim Grogan | - | - | - | - | - | - |
| **Key management personnel** | | | | | | |
| Drew Speedy | - | - | - | - | - | - |
| Edmond Tern | - | - | - | - | - | - |

Participants need to be appointed as a director or employed by the company at the vesting date. Unvested shares are bought back by the Company at the cessation of appointment or employment at the issue price.

**Equity Incentive Plan**

At the 2024 Annual General Meeting, shareholders approved an equity incentive plan which would be replacing LSP enabling the Company to grant or issue options or any other equity securities in the Company under the Equity Incentive Plan, and to issue ordinary shares in the Company upon the vesting or exercise of options under the Equity Incentive Plan, to be exempted from counting towards the rolling annual limit of 15% of issued ordinary shares in the Company prescribed by ASX Listing Rule 7.1.

**Share-based Compensation**

There were no equity awards under the Company's STI or LTI for the year ending 30 June 2026 and year ending 30 June 2025.

**Key Management Personnel Equity Holdings**

**Shareholdings**

Fully paid ordinary shares and shares under the Loan Share Plan held by key management personnel or their related parties:

| 2026 | Balance on 1 July | Granted as Compensation | Forfeited/ Cancelled | Net change other[(1)] | Balance on 30 June | Vested Loan Share Plan Shares |
|---|---|---|---|---|---|---|
| Alex Ding | 12,382,951 | - | - | 21,739,130 | 34,122,081 | - |
| Andrew Guthrie | 267,059 | - | - | 217,392 | 484,451 | - |
| Chris Ramsey | 119,000 | - | - | - | 119,000 | - |
| Peter May | 1,842,205 | - | - | 217,392 | 2,059,597 | 1,320,316 |
| Tim Grogan | 59,524 | - | - | 217,392 | 276,916 | - |
| Drew Speedy | - | - | - | - | - | - |
| Edmond Tern | - | - | - | - | - | - |
| **Totals** | **14,670,739** | **-** | **-** | **22,391,306** | **37,062,045** | **1,320,316** |

For personal use only

(1) Key Management Person participated in the 2025 Placement during the reporting period following shareholder approval.

| 2025 | Balance on 1 July | Granted as Compensation | Forfeited/ Cancelled | Net change other | Balance on 30 June | Vested Loan Share Plan Shares |
|---|---|---|---|---|---|---|
| Alex Ding | 12,382,951 | - | - | - | 12,382,951 | - |
| Andrew Guthrie | 267,059 | - | - | - | 267,059 | - |
| Chris Ramsey | 119,000 | - | - | - | 119,000 | - |
| Peter May | 1,842,205 | - | - | - | 1,842,205 | 1,320,316 |
| Tim Grogan | 59,524 | - | - | - | 59,524 | - |
| Edmond Tern | - | - | - | - | - | - |
| **Totals** | **14,670,739** | **-** | **-** | **-** | **14,670,739** | **1,320,316** |

**Options**

Options held by key management personnel:

| 2026 | Balance on 1 July | Granted as Compensation | Other[(1)] | Expired | Exercised | Balance on 30 June | Total vested and exercisable on 30 June |
|---|---|---|---|---|---|---|---|
| Alex Ding | - | - | 21,739,130 | - | - | 21,739,130 | 21,739,130 |
| Andrew Guthrie | - | - | 217,392 | - | - | 217,392 | 217,392 |
| Chris Ramsey | - | - | - | - | - | - | - |
| Peter May | - | - | 217,392 | - | - | 217,392 | 217,392 |
| Tim Grogan | - | - | 217,392 | - | - | 217,392 | 217,392 |
| Drew Speedy | - | - | - | - | - | - | - |
| Edmond Tern | - | - | - | - | - | - | - |
| **Totals** | **-** | **-** | **22,391,306** | **-** | **-** | **22,391,306** | **22,391,306** |

(1) Key Management Person participated in the 2025 Placement during the reporting period following shareholder approval which included free attaching options.

On 30 June 2025 no Options were held by the key management personnel.

**Voting and comments made at the company's 2025 annual general meeting:**

Bio-Gene Technology Limited received more than 98.99% of "yes" votes for the adoption of the Remuneration Report for the 2025 financial year.

**END OF REMUNERATION REPORT**

For personal use only

## Options

At the date of this report, the unissued ordinary shares of the Company under options are as follows:

| Grant Date | Expiry Date | Exercise Price | No. of Options |
|---|---|---|---|
| 18 July 2025 | 15 May 2028 | $0.034 | 55,035,096 |
| 18 July 2025 | 15 May 2030 | $0.048 | 55,035,096 |
| 10 August 2026 | 15 October 2027 | $0.035 | 69,221,150 |
| **Totals** | | | **179,291,342** |

No ordinary shares were issued during and since the year ended 30 June 2026 on the exercise of options.

Option holders do not have any rights to participate in any share issue or other interests in the Company or any other entity.

## Events since the end of the financial year

On 5 August 2026, the Company held a Shareholders meeting to consider key resolutions including:


- Issue of placement shares to related parties
- Issue of SPP shortfall shares as per the SPP Underwriting Agreement
- Issue of unlisted options tied to placement shares, Share Purchase Plan (SPP) shares, SPP Underwriting and the lead manager for a recent capital raise

All resolutions were passed with >96% shareholder approval, reflecting strong investor support.

On 10 August 2026, the Company issued the following securities in relation to the Capital raising activities:

- 34,760,000 fully paid ordinary shares, raising A$869,000 (before costs) in relation to Tranche 2 of the placement;
- 15,220,000 fully paid ordinary shares, raising A$380,500 (before costs) in relation to the SPP Underwriting Agreement;
- 2,000,000 fully paid shares to an Advisor to the capital raising activities in relation to services provided; and
- 69,221,150 options exercisable at 3.5 cents per option expiring on 15 October 2027.

This report is made in accordance with a resolution of the Directors.



**Mr. Alex Ding**

**Non-Executive Chair**

Date: 28 August 2026

For personal use only

Horizon Nexus (Audit) Pty Ltd (ABN 33 692 918 577)
Level 4, 35 Collins Street, Melbourne, Victoria, 3000
PO Box 24155, Melbourne, Victoria 3001
horizonnp.com.au

**AUDITOR'S INDEPENDENCE DECLARATION**
**UNDER 307C OF THE CORPORATIONS ACT 2001**
**TO THE DIRECTORS OF BIO-GENE TECHNOLOGY PTY LTD**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2026 there have been:

(i) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and

(ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Horizon Nexus (Audit) Pty Ltd

**Horizon Nexus (Audit) Pty Ltd**
ABN 33 692 918 577

**Sam Claringbold**
Director
Melbourne, 28th August 2026

For personal use only

Liability limited by a scheme approved under Professional Standards Legislation.

# CORPORATE GOVERNANCE

The Board of Directors of Bio-Gene Technology Limited (Board) is responsible for the corporate governance of the Company. The Board guides and monitors the business and affairs of the Company on behalf of the shareholders by whom they are elected and to whom they are accountable.

The Board supports the core corporate governance principles published by the ASX Corporate Governance Council (Council). The Company's corporate governance framework is designed to comply with the Council's principles whilst being relevant, efficient and cost effective for the current stage of the Company's development.

The Corporate Governance Statement contains certain specific information and discloses the extent to which the Company has followed the Council's principles during the 2026 financial year. Bio-Gene's Corporate Governance Statement is structured with reference to the ASX Corporate Governance Principles and Recommendations 4th Edition and can be found on the Bio-Gene website at Corporate Governance - Bio-Gene Technology Limited.

The Board will continue its ongoing review process to ensure that the model is relevant, efficient and cost effective to the Company and its shareholders.

For personal use only

# BIO-GENE TECHNOLOGY LIMITED
# ABN 32 071 735 950
# STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
# FOR THE YEAR ENDED 30 JUNE 2026

| | Note | 2026 $ | 2025 $ |
|---|---|---|---|
| Other income | 3(a) | 1,078,888 | 524,370 |
| | | **1,078,888** | **524,370** |
| **Expenses from continuing operations** | 3(b) | | |
| Research & Development | | (1,767,259) | (1,379,650) |
| Commercialisation Expenses | | (450,807) | (556,925) |
| Intellectual Property | | (336,472) | (245,779) |
| Professional Services | | (133,380) | (73,790) |
| Directors Expenses | | (187,145) | (189,114) |
| Management & Corporate Expenses | | (486,948) | (621,652) |
| Depreciation & Amortisation | | (42,003) | (41,928) |
| Other expenses | | (5,679) | - |
| **Loss from continuing operations before tax** | | **(2,330,805)** | **(2,584,468)** |
| Income tax (expense) | 21 | - | - |
| **Loss for the year from continuing operations after income tax** | | **(2,330,805)** | **(2,584,468)** |
| Other comprehensive income | | - | - |
| Items that may be reclassified subsequently to profit or loss | | | |
| **Total comprehensive loss for the year attributable to members of the Company** | | **(2,330,805)** | **(2,584,468)** |

| **Earnings per share:** | **Note** | **2026** | **2025** |
|---|---|---|---|
| Basic loss per share - from continuing operations | 4 | (0.75¢) | (1.22¢) |
| Diluted loss per share - from continuing operations | 4 | (0.75¢) | (1.22¢) |

The above Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

For personal use only

# BIO-GENE TECHNOLOGY LIMITED
# ABN 32 071 735 950
# STATEMENT OF FINANCIAL POSITION
# AS AT 30 JUNE 2026

For personal use only

| | Note | 2026 $ | 2025 $ |
|---|---|---|---|
| **Current assets** | | | |
| Cash and cash equivalents | 5 | 1,939,590 | 1,138,338 |
| Trade and other receivables | 6 | 407,639 | 472,424 |
| Other current assets | 7 | 125,440 | 359,644 |
| **Total current assets** | | **2,472,669** | **1,970,406** |
| **Non-current assets** | | | |
| Property, plant and equipment | 8 | 8,291 | 13,351 |
| Intangible assets | 9 | 129,299 | 166,242 |
| **Total non-current assets** | | **137,590** | **179,593** |
| **Total assets** | | **2,610,259** | **2,149,999** |
| **Current liabilities** | | | |
| Trade and other payables | 10 | 354,492 | 310,463 |
| Employee benefits | 11 | 162,937 | 148,459 |
| Financial liabilities | 12 | - | 51,209 |
| **Total current liabilities** | | **517,429** | **510,131** |
| **Non-current liabilities** | | | |
| Employee benefits | 11 | 2,335 | 12,852 |
| **Total non-current liabilities** | | **2,335** | **12,852** |
| **Total liabilities** | | **519,764** | **522,983** |
| **Net assets** | | **2,090,495** | **1,627,016** |
| **Equity** | | | |
| Issued capital | 13 | 25,714,440 | 22,944,866 |
| Reserves | 14(a,b) | 575,468 | 712,090 |
| Accumulated losses | 14(c) | (24,199,413) | (22,029,940) |
| **Total equity** | | **2,090,495** | **1,627,016** |

The above Statement of Financial Position should be read in conjunction with the accompanying notes.

# BIO-GENE TECHNOLOGY LIMITED
# ABN 32 071 735 950
# STATEMENT OF CHANGES IN EQUITY
# FOR THE YEAR ENDED 30 JUNE 2026

| 2026 | Note | Fully paid ordinary shares $ | Share option reserve $ | Share loan plan reserve $ | Accumulated losses $ | Total $ |
|---|---|---|---|---|---|---|
| **At 1 July 2025** | | **22,944,866** | **-** | **712,090** | **(22,029,940)** | **1,627,016** |
| Loss for the period | | - | - | - | (2,330,805) | (2,330,805) |
| Other comprehensive income | | - | - | - | - | - |
| **Total comprehensive income/(loss) for the year** | | **-** | **-** | **-** | **(2,330,805)** | **(2,330,805)** |
| Transactions with owners in their capacity as owners: | | | | | | |
| Issued capital | | 2,990,621 | - | - | - | 2,990,621 |
| Transaction costs related to shares issued | | (221,047) | 24,710 | - | - | (196,337) |
| Re-allocation of value of equity on forfeiture of loans on shares | | - | - | (161,332) | 161,332 | - |
| **At 30 June 2026** | | **25,714,440** | **24,710** | **550,758** | **(24,199,413)** | **2,090,495** |

| 2025 | Note | Fully paid ordinary shares $ | Share option reserve $ | Share loan plan reserve $ | Accumulated losses $ | Total $ |
|---|---|---|---|---|---|---|
| **At 1 July 2024** | | **21,524,527** | **194,947** | **712,090** | **(19,640,420)** | **2,791,144** |
| Loss for the period | | - | - | - | (2,584,468) | (2,584,468) |
| Other comprehensive income | | - | - | - | - | - |
| **Total comprehensive income/(loss) for the year** | | **-** | **-** | **-** | **(2,584,468)** | **(2,584,468)** |
| Transactions with owners in their capacity as owners: | | | | | | |
| Issued capital | | 1,496,328 | - | - | - | 1,496,328 |
| Transaction costs related to shares issued | | (75,989) | - | - | - | (75,989) |
| Re-allocation of value of equity on forfeiture of loans on shares | | - | (194,947) | - | 194,947 | - |
| Cost of share-based payment | 14 (a,b) | - | - | - | - | - |
| **At 30 June 2025** | | **22,944,866** | **-** | **712,090** | **(22,029,940)** | **1,627,016** |

The above Statement of Changes in Equity should be read in conjunction with the accompanying notes.

For personal use only

# BIO-GENE TECHNOLOGY LIMITED
# ABN 32 071 735 950
# STATEMENT OF CASH FLOWS
# FOR THE YEAR ENDED 30 JUNE 2026

| | Note | 2026 $ | 2025 $ |
|---|---|---|---|
| **Cash flows from operating activities** | | | |
| Receipts from customers | | - | - |
| Payments to suppliers and employees inclusive of GST | | (3,074,044) | (3,118,066) |
| Interest received | | 24,908 | 39,663 |
| Interest paid | | (2,559) | - |
| R&D tax incentive | | 519,502 | 535,635 |
| Other income | | 593,488 | - |
| **Net cash used in operating activities** | 15(b) | **(1,938,705)** | **(2,542,768)** |
| **Cash flows from investing activities** | | | |
| Payments for property, plant and equipment | | - | - |
| **Net cash used in investing activities** | | **-** | **-** |
| **Cash flows from financing activities** | | | |
| Proceeds from issue of shares | | 2,990,621 | 1,496,328 |
| Payment for share issue expenses | | (196,337) | (75,989) |
| Proceeds from financial liabilities | | (51,209) | 51,209 |
| **Net cash provided by financing activities** | | **2,743,075** | **1,471,548** |
| Net increase in cash and cash equivalents | | 804,370 | (1,071,220) |
| Net foreign exchange difference | | (3,118) | - |
| Cash and cash equivalent at beginning of year | | 1,138,338 | 2,209,558 |
| **Cash and cash equivalents at end of year** | 15(a) | **1,939,590** | **1,138,338** |

The above Statement of Cash Flows should be read in conjunction with the accompanying notes.

For personal use only

For personal use only

## Introduction

The financial report covers Bio-Gene Technology Limited ("Bio-Gene" or "Company"), as an individual entity.

Bio-Gene is a listed public company limited by shares, incorporated and domiciled in Australia. The presentation currency and functional currency of the Company is Australian dollars.

The principal activity of the Company during the financial year was developing insecticides/pesticides.

The registered office address of the Company is Quinert Rodda and Associates, Level 6, 400 Collins Street, Melbourne, Victoria 3000.

The financial report was authorised for issue by the Board of Directors of Bio-Gene on the date shown on the Declaration by Directors attached to the Financial Statements.

## Note 1: Statement of Material Accounting Policies

The financial report is a general-purpose financial report which has been prepared in accordance with the *Corporations Act 2001*, Australian Accounting Standards and Interpretations, and complies with other requirements of the law. Bio-Gene is a for-profit entity for the purpose of preparing these financial statements.

These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (IASB).

The financial report has been prepared on an accruals basis and are based on historical cost, except for the revaluation of certain non-current assets and financial instruments. Cost is based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars unless otherwise noted. All values are rounded to the nearest dollar.

The accounting policies have been consistently applied and, except where there is a change in accounting policy, are consistent with those of the previous year.

The principal accounting policies which have been adopted in the preparation of these financial statements are set out below.

***Going concern***

The financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

During the financial period ended 30 June 2026 the Company incurred an operating loss of $2,330,805 (2025: $2,584,468) and a negative cash outflow from operating activities of $1,938,705 (2025: $2,542,768). The ability of the Company to continue as a going concern is dependent on securing additional funding through new or existing investors to fund its operational and marketing activities. These conditions indicate a material uncertainty that may cast a significant doubt about the entity's ability to continues as going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The Directors believe that there are reasonable grounds to believe the Company will continue as a going concern after considering the following factors:

The Company has prepared budgets and a cash flow forecast for the next 12 months which indicate the Company will have a positive cash balance during this period. This cash flow forecast includes further capital raising and receipts from the research and development tax rebate over that period.

The Directors believe that there are reasonable grounds to expect the Company has the capacity to raise capital. The Company has a strong track record of accessing capital when it is required (refer note 13 for issue of shares during the year totalling $2,990,621 as part of the equity fundraising efforts).

Accordingly, the Directors believe it is appropriate for the financial statements to be prepared on a going concern basis.

No adjustments have been made relating to the recoverability and classification of assets and liabilities that might be necessary should the Company not continue as going concern.

***Critical accounting judgements and key sources of estimation uncertainty***

In the application of the Company's accounting policies, which are described below, management is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstance, the results of which form the basis of making the judgements. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements made in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements concerns management's review of finite life intangibles for indicators of impairment. The carrying amount of intangibles at 30 June 2026 is $129,299 (2025: $166,242). Refer to Note 9 for details of the assumptions made on the carrying value of Intangibles.

At each reporting period the Company assesses whether finite life intangibles have suffered any impairment in accordance with the accounting policy stated in this Note.

The Going Concern assumption also requires significant estimates, mainly in relation to expected cash inflows and outflows from various alternatives available to the Company.

Other areas that require significant judgement and key assumptions include share-based payments, which are calculated at fair value using industry standard option pricing models, and the estimated useful life of intangibles, which is based understanding of competitive forces, and general familiarity with the market.

There have been no other significant judgments made in applying accounting policies that the Directors consider would have a significant effect on the amounts recognised in the financial statements. There have been no key assumptions made concerning the future, and there are no other key sources of estimation uncertainty at the reporting date, that the Directors consider would have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

For personal use only

For personal use only

***Property, plant and equipment***

The purchase method of accounting is used for all acquisitions of assets. Cost is measured as the fair value of the assets given up, shares issued or liabilities undertaken at the date of acquisition plus incidental costs directly attributable to the acquisition.

Property, plant and equipment is recognised at cost and are depreciated over their estimated useful lives using the straight-line method. The expected useful life for property, plant and equipment is:

- Computer equipment – 2 years; and
- Plant and equipment – 10 years.

Profits and losses on disposal of plant and equipment are taken into account in determining the result for the year.

**Impairment**

The carrying values of plant and equipment are reviewed for impairment at each reporting date with recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired. Impairment exists when the carrying value of an asset exceeds its estimated recoverable amount. The asset is then written down to its recoverable amount.

Impairment losses are recognised in the statement of profit or loss and other comprehensive income.

***Intangible assets***

Licences have a finite useful life and are carried at cost less accumulated amortisation and impairment losses.

Amortisation is calculated using the straight-line method, over the assets estimated useful lives of 20 years.

***Research and development costs***

Research and development expenditure is expensed as incurred except to the extent that its future recoverability can reasonably be regarded as assured, in which case it is deferred and amortised on a straight-line basis over the period in which the related benefits are expected to be realised.

The carrying value of development costs that have been capitalised are reviewed for impairment annually when the asset is not yet in use or when an indicator of impairment arises during the reporting year indicating that the carrying value may not be recoverable.

***Share based payments***

Equity settled share-based payments with employees, key consultants providing similar services and Directors are measured at fair value at the date of issue. Fair value is measured by use of industry standard pricing models. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

The fair value determined at the issue date of the equity settled share-based payments is expensed on a straight-line basis over the vesting period, based on the entity's estimate of shares that will eventually vest.

For cash settled share-based payments, a liability equal to the portion of the goods or services received is recognised at the current fair value determined at each reporting date.

For personal use only

***Income taxes***

Income taxes are accounted for using the comprehensive statement of financial position liability method whereby:

- the tax consequences of recovering (settling) all assets (liabilities) are reflected in the financial statements;
- current and deferred tax is recognised as income or expense except to the extent that the tax relates to equity items or to a business combination;
- a deferred tax asset is recognised to the extent that it is probable that future taxable profit will be available to realise the asset; and
- deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability settled.

Unused tax losses for which no deferred tax asset has been recognised are $18,474,578 (2025: $16,533,435) resulting in a potential tax benefit at 25.0% of $4,618,645 (2025: $4,133,359), current financial year tax lodgement is in progress. The unused tax losses were incurred as part of the company's research and development activities. They can be carried forward indefinitely provided that the Company satisfies the "same business", "similar business test" or "continuity of ownership" tests.

**Revenue recognition**

**Licence and option fee revenue**

Licence and option fee revenue is recognised in accordance with the underlying agreement. Licence and options fees are recognised in accordance with AASB15 Revenue from Contracts with Customers. The core principle of AASB15 is that revenue is recognised on a basis that reflects the transfer of promised goods or services to customers at an amount that reflects the consideration the Company expects to receive in exchange of those goods and services.

**Research collaboration income**

Research collaboration income are recognised in accordance with the underlying agreement. Payments are brought to account as revenues at the time that the relevant milestone has been achieved.

**Interest income**

Interest income is recognised on a time proportion basis using the effective interest method.

When a receivable is impaired, the Company reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument and continues unwinding the discount as interest income. Interest income on impaired loans is recognised using the original effective interest rate.

**R&D tax incentive**

Income from the R&D Tax Incentive is recognised on an accruals basis when AusIndustry accept the claim or there is a reasonable probability that AusIndustry will accept the claim.

**Grant income**

Grants are recognised in profit or loss on a systematic basis when conditions relating to the grant are satisfied and it is reasonably certain that the grant will be received.

For personal use only

### Sales

Sales are recognised when the goods have been delivered to the purchaser.

### New Accounting Standards and Interpretations

At 30 June 2026, a number of accounting standards and amendments had been issued but were not yet mandatory for the Group. Management has not early adopted these standards. The most significant forthcoming change is **AASB 18 Presentation and Disclosure in Financial Statements**, which will modify the presentation of the statement of profit or loss and introduce additional disclosure requirements relating to management-defined performance measures and the aggregation/disaggregation of information. Management is currently assessing the potential impact on the Group's financial statements and related reporting processes. Based on the assessment performed to date, no other issued but not yet effective standards are expected to have a material impact on the Group's financial position or results of operations.

## Note 2: Remuneration of auditors

| | 2026<br>$ | 2025<br>$ |
|---|---|---|
| **Audit services** | | |
| **Horizon Nexus (Audit) Pty Ltd** | | |
| Audit and review of financial reports and other audit work under the *Corporations Act 2001* | 24,000 | - |
| **MVA Bennett Assurance** | | |
| Audit and review of financial reports and other audit work under the *Corporations Act 2001* | 12,010 | 35,000 |
| **Total remuneration for audit services** | **36,010** | **35,000** |
| **Other advisory services provided by firms associated with the audit firm** | | |
| **Horizon Nexus (Audit) Pty Ltd** | | |
| Advice on taxation and other matters and review and lodgement of corporate tax returns | - | - |
| **MVA Bennett** | | |
| Advice on taxation and other matters and review and lodgement of corporate tax returns | 7,000 | 7,000 |
| **Total remuneration for other services** | **7,000** | **7,000** |

For personal use only

## Note 3: Other income and expenses

| | 2026 $ | 2025 $ |
|---|---|---|
| **(a) Other income** | | |
| R&D tax incentive | 469,502 | 385,635 |
| Interest received | 24,908 | 39,438 |
| Research grants | 584,478 | 95,835 |
| Other Income | - | 3,462 |
| **Total other income** | **1,078,888** | **524,370** |
| | | |
| **(b) Expenses** | | |
| **Loss before income tax includes the following specific expenses:** | | |
| **Research & Development expenses:** | | |
| Consulting | 543,476 | 135,543 |
| Salaries and employee benefits | 437,646 | 514,875 |
| Studies and development | 774,472 | 712,013 |
| Other | 11,664 | 17,219 |
| **Total research & development expenses** | **1,767,259** | **1,379,650** |
| | | |
| **Commercialisation expenses:** | | |
| Farm management | 45,629 | 60,467 |
| Salaries and employee benefits | 405,178 | 496,458 |
| | **450,807** | **556,925** |
| | | |
| **Intellectual Property:** | | |
| Professional services | **336,472** | **245,790** |
| | | |
| **Depreciation, amortisation and impairment of non-current assets:** | | |
| Plant and equipment | 5,060 | 5,660 |
| License and registered patents | 36,943 | 36,943 |
| **Total depreciation and amortisation expenses** | **42,003** | **42,603** |
| | | |
| **Foreign currency exchange differences:** | | |
| Foreign currency exchange losses | **3,118** | **-** |

For personal use only

## Note 4: Earnings per share

| | 2026 $ | 2025 $ |
|---|---|---|
| Net loss used in calculating basic earnings per share: | 2,330,805 | 2,584,468 |
| Net loss used in calculating diluted earnings per share: | 2,330,805 | 2,584,468 |
| | **No. of Shares** | **No. of Shares** |
| Weighted average number of ordinary shares used in calculating basic earnings per share | 309,109,897 | 185,817,655 |
| Dilutive potential ordinary shares | | |
| Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted earnings per share | **309,109,897** | **185,817,655** |

## Information concerning the classification of securities

## Fully paid ordinary shares

Fully paid ordinary shares carry the right to participate in dividends and the proceeds on winding up of the Company in equal proportion to the number of shares held. At shareholder meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands. Fully paid ordinary shares are included as ordinary shares in the determination of basic earnings per share.

## Loan Share Plan

The Loan Share Plan (LSP) allows non-recourse, interest free loans to be provided to eligible participants to acquire shares under the plan. When an issue is made it will be treated as an in-substance grant of options and expensed over the vesting period because of the limited recourse nature of the loans. Shares offered under the LSP may be subject to Vesting Conditions, Forfeiture Conditions and Disposal Restrictions (collectively referred to as “Conditions”) as determined by the Board and specified in the Offer documents sent to participants. The Board has discretion to waive or deem Conditions to have been satisfied. Shares under the LSP cannot be dealt with (including traded on the ASX) unless they are not subject to any Conditions and there is no outstanding Loan on the shares.

Generally, shares issued under the plan will vest over a 6 or 12 month period. The shares are acquired in the name of the participant and each participant authorises and appoints the Company Secretary to act on their behalf. Any dividends paid on the shares are used to repay the loan. In all other respects the shares issued under the LSP carry the same rights as other ordinary shares on issue. If the participant leaves the Company, any shares that have not vested will be bought back by the Company and cancelled along with the loan. In respect of shares that have vested the loan balance must be paid in full within six months of termination or the shares will be sold and the proceeds applied to settle the loan balance. The issue price of the shares in the Company held under the LSP is not included in equity until the loan has been repaid.

Amounts unpaid on shares held under the LSP are treated as the equivalent of options to acquire ordinary shares and are excluded as potential ordinary shares in the determination of diluted earnings per share and basic earnings per share. Details relating to the LSP are set out in Note 13(c).

The 6,060,902 shares on issue at reporting date that were granted under the LSP are not included in the calculation of diluted earnings per share because they are anti-dilutive for the year ended 30 June 2026. These shares could potentially dilute basic earnings per share in the future.

For personal use only

## Options

Options granted by the Company are considered to be potential ordinary shares and have been excluded in the determination of diluted earnings per share to the extent to which they are dilutive. The options have not been included in the determination of basic earnings per share because they are anti-dilutive for the year ended 30 June 2026. Details relating to the options are set out in Note 13(b).

## Note 5: Cash and cash equivalents

| | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| Cash at bank | 388,268 | 79,327 |
| Deposit at call | 1,551,322 | 559,011 |
| Term deposits | - | 500,000 |
| | **1,939,590** | **1,138,338** |

Funds placed on term deposit are invested for a maximum of 90 days and therefore considered to be cash equivalents. During and at the end of the Reporting Period, interest rates on deposits at call were more favourable than interest rates on term deposits.

## Note 6: Trade and other receivables

| | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| R&D tax incentive | 300,000 | 350,000 |
| Grant receivable | 86,825 | 95,835 |
| GST refund due | 20,814 | 26,589 |
| | **407,639** | **472,424** |

The balance of Trade and other receivables of $407,639 (2025: $472,424) is not past due and not considered impaired.

## Note 7: Other current assets

| | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| Prepayments | 55,440 | 289,644 |
| Security deposits | 70,000 | 70,000 |
| | **125,440** | **359,644** |

For personal use only

## Note 8: Property, plant and equipment

| | 2026 $ | 2025 $ |
|---|---|---|
| **Plant and equipment** | | |
| At cost | 56,239 | 56,239 |
| Accumulated depreciation | (47,948) | (42,888) |
| **Total net plant and equipment** | **8,291** | **13,351** |

Movements in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year.

| | 2026 $ | 2025 $ |
|---|---|---|
| **Plant and equipment** | | |
| Balance at the beginning of year | 13,351 | 19,010 |
| Additions | - | - |
| Disposals | - | - |
| Depreciation expense, impairment and asset write off | (5,060) | (5,659) |
| **Carrying amount at the end of year** | **8,291** | **13,351** |

## Note 9: Intangible assets

| | 2026 $ | 2025 $ |
|---|---|---|
| Licences - Qcide | 557,818 | 557,818 |
| Less: Accumulated amortisation | (428,519) | (391,576) |
| **Total net intangible assets** | **129,299** | **166,242** |

Movements in the carrying amounts for intangible assets between the beginning and the end of the current financial year

| | | |
|---|---|---|
| Carrying amount at the beginning of year | **166,242** | **203,185** |
| Additions – acquisitions | - | - |
| Amortisation expense[(a)] | (36,943) | (36,943) |
| **Carrying amount at the end of year[(b)]** | **129,299** | **166,242** |

(a) Intangible assets comprise licences in relation to Qcide, which has a finite useful life and is recorded at cost. Amortisation has been historically calculated using straight line method over the estimated useful life of 20 years.
(b) Intangible assets are reviewed on a regular basis and where a decision has been made not to pursue a product, the remaining value recorded as an asset is impaired. At balance date, the directors also review the intellectual property portfolio to determine whether there are any indicators of impairment related to intellectual property.

## Note 10: Trade and other payables

| | 2026 $ | 2025 $ |
|---|---|---|
| Trade creditors | 223,544 | 83,001 |
| Accrued expenses | 65,904 | 139,122 |
| Other payables | 65,044 | 88,340 |
| | **354,492** | **310,463** |

## Note 11: Employee benefits

| | 2026 $ | 2025 $ |
|---|---|---|
| **Current** | | |
| Annual leave entitlements | 121,424 | 120,364 |
| Long service leave entitlements | 41,513 | 28,095 |
| | **162,937** | **148,459** |
| **Non-current** | | |
| Long service leave entitlements | 2,335 | 12,852 |
| | **2,335** | **12,852** |

## Note 12: Financial liabilities

| | 2026 $ | 2025 $ |
|---|---|---|
| **Current** | | |
| Insurance premium funding liabilities | - | 51,209 |
| | **-** | **51,209** |

## Note 13: Contributed equity

The Company does not have authorised capital nor par value in respect of its issued shares.

Ordinary shares participate in dividends and the proceeds on winding up of the Company in equal proportion to the number of shares held. At shareholder meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

For personal use only

For personal use only

**(a) Movements in issued capital during the year were as follows:**

| | 2026 No. | 2025 No. | 2026 $ | 2025 $ |
|---|---|---|---|---|
| At the beginning of the reporting period | **266,419,324** | **201,361,570** | **22,944,866** | **21,524,527** |
| May 25 Placement Share Tranche 1 | - | 50,340,392 | - | 1,157,829 |
| May 25 Placement Share Tranche 2 | 41,961,784 | - | 965,121 | - |
| May 25 Share Purchase Plan | - | 14,717,362 | - | 338,499 |
| June 26 Placement Share Tranche 1 | 76,240,000 | - | 1,906,000 | - |
| June 26 Share Purchase Plan | 4,780,000 | - | 119,500 | - |
| Capital raising costs | - | - | (221,047) | (75,989) |
| Cancellation of LSP Shares | (3,320,000) | - | - | - |
| **At end of the reporting period** | **386,081,108** | **266,419,324** | **25,714,440** | **22,944,866** |

**(b) Movements in share options over ordinary shares during the year were as follows:**

| | 2026 No. | 2025 No. |
|---|---|---|
| Balance at beginning of the year | **-** | **2,500,000** |
| Exercised during the year | - | - |
| Expired during the year | - | (2,500,000) |
| Issued during the period | 110,070,192 | - |
| **Balance at end of the year** | **110,070,192** | **-** |

| **Terms of options issued** | **Tranche 1** | **Tranche 2** |
|---|---|---|
| Options issued | 55,035,096 | 55,035,096 |
| Issue date | 18-Jul-2025 | 18-Jul-2025 |
| Exercise Price | 3.4 cents | 4.6 cents |
| Expiry | 15-May-2028 | 15-May-2030 |

- The weighted average remaining contractual life of the options was 2.87 years (2025: Nil) and the weighted average exercise price was 4.0 cents (2025: Nil).
- Share options granted carry no rights to dividends and no voting rights.

**(c) Loan Share Plan**

The Company issues shares to Bio-Gene directors, executives and key consultants under the Loan Share Plan (LSP). Under the plan, participants are issued with equity to foster an ownership culture within the Company and to motivate them to achieve performance targets. Participation in the plan is at the Board's discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.

The Company introduced the LSP. The plan allows for shares to be issued for a nominal value or for non-recourse, interest free loans to be provided to eligible participants to acquire shares under the plan. Shares issued under the plan vest in accordance with the Executive Remuneration Strategy and Structure (refer to Remuneration Report for details).

When an issue is made at nominal value it is expensed over the vesting period. If the participant leaves the Company, any shares that have not vested are bought back by the Company and cancelled. When an issue is made, and a loan is provided, it is treated as an in-substance grant of options and expensed over the vesting period because of the limited recourse nature of the loans. Each participant authorises and appoints the Company Secretary to act on their behalf. Any dividends paid on the shares are used to repay the loan. If the participant leaves the Company, any shares that have not vested are bought back by the Company and

For personal use only

cancelled along with the loan. In respect of shares that have vested, generally, the loan balance must be paid in full within six months of termination of appointment or the shares are sold and the proceeds applied to settle the loan balance. The issue price of the shares in the Company held under the LSP is not included in equity until the loan has been repaid.

The valuations of shares issued under the LSP are determined by using an industry standard option pricing model taking into account the terms and conditions upon which the instruments were issued.

**Shares in existence in the current and past period under the Loan Share Plan:**

Following the consolidation of the Company's equity in September 2017, all share numbers are reported on a post consolidation basis.

| | Loan Share Plan Tranche | | | | | |
|---|---|---|---|---|---|---|
| | **Number** | **Issue date** | **Vesting Date** | **Loan expiry date** | **Unit Price $** | **Fair Value at Issue Date $** |
| Tranche 1a[1,9] | 2,500,000 | 29/06/2015 | 29/06/2015 | 29/12/2025 | 0.034 | 85,000 |
| Tranche 2a[1,9] | 320,000 | 30/06/2016 | 30/06/2016 | 29/12/2025 | 0.0334 | 13,894 |
| Tranche 2b[7] | 96,000 | 30/06/2016 | 30/06/2016 | 30/06/2026 | 0.0334 | 13,894 |
| Tranche 3a[1,9] | 500,000 | 11/05/2017 | 11/11/2017 | 29/12/2025 | 0.0622 | 50,538 |
| Tranche 3b[7] | 312,500 | 11/05/2017 | 11/11/2017 | 11/05/2027 | 0.0622 | 50,538 |
| Tranche 3c[7] | 812,500 | 11/05/2017 | 11/05/2018 | 11/05/2027 | 0.0622 | 50,538 |
| Tranche 4a[7] | 187,500 | 26/07/2017 | 26/01/2018 | 26/07/2027 | 0.0922 | 17,288 |
| Tranche 4b[7] | 187,500 | 26/07/2017 | 26/07/2018 | 26/07/2027 | 0.0894 | 16,763 |
| Tranche 5a | 500,000 | 4/12/2017 | 4/06/2018 | 4/12/2025 | 0.1314 | 65,700 |
| Tranche 5b | 500,000 | 4/12/2017 | 4/12/2018 | 4/12/2025 | 0.1275 | 63,750 |
| Tranche 6[2] | 263,304 | 6/12/2018 | 1/01/2019 | N/A | 0.1311 | 34,519 |
| Tranche 9[3] | 507,162 | 1/11/2019 | 1/11/2019 | N/A | 0.1411 | 71,560 |
| Tranche 10[6] | 2,201,972 | 1/11/2019 | 30/06/2022 | 1/11/2026 | 0.0789 | 173,736 |
| Tranche 11a[8] | 383,509 | 1/11/2019 | 30/06/2020 | N/A | 0.1411 | 54,113 |
| Tranche 11b[8] | 383,508 | 1/11/2019 | 30/06/2021 | N/A | 0.1411 | 54,113 |
| Tranche 11c[8] | 383,507 | 1/11/2019 | 30/06/2022 | N/A | 0.1411 | 54,112 |
| Tranche 12[4] | 493,881 | 30/07/2020 | 28/08/2020 | N/A | 0.1399 | 69,094 |
| Tranche 13[6] | 1,262,930 | 30/07/2020 | 30/06/2023 | 30/07/2027 | 0.0789 | 106,465 |
| Tranche 14a[5] | 253,424 | 30/07/2020 | 30/06/2021 | N/A | 0.1399 | 35,454 |
| Tranche 14b[5] | 253,424 | 30/07/2020 | 30/06/2022 | N/A | 0.1399 | 35,454 |
| Tranche 14c[5] | 253,422 | 30/07/2020 | 30/06/2023 | N/A | 0.1399 | 35,454 |
| | **12,556,043** | | | | | **1,151,977** |
| Revaluation of pre IPO Shares[7] | | | | | | 68,418 |
| Less Unexpensed portion of valuation | | | | | | - |
| Less Shares Cancelled during previous years[5] | (1,910,794) | | | | | (333,132) |
| Less Shares Cancelled during current year | (3,320,000) | | | | | (161,332) |
| Less Unrestricted Shares | (1,264,347) | | | | | (175,173) |
| | **6,060,902** | | | | | **550,758** |

1. The Loan expiry date on the Tranche 1a shares is now 29 December 2024 (from 29 June 2025), the Loan expiry date on the Tranche 2a shares is now 29 December 2024 (from 30 June 2026) and the

For personal use only

Loan expiry date on the Tranche 3a shares is now 29 December 2024 (from 11 May 2027), in each case, due to the termination of appointment of a Loan Share Plan participant.

2. The Tranche 6 shares were issued in respect of the executives' short-term incentive for the 2018 financial year and vested on 1 January 2019.
3. The Tranche 9 shares were issued in respect of the executives' and employee's short-term incentives for the 2019 financial year and vested on 1 November 2019.
4. The Tranche 12 shares were issued in respect of the executives' and employee's short-term incentives for the 2020 financial year and vested on 28 August 2020.
5. Tranches 14a, 14b and 14c were forfeited and have been cancelled on 27 July 2023.
6. The Tranche 10 shares vested on 30 June 2022 and the tranche 13 shares vested on 30 June 2023.
7. The loan period for the Tranche 2b, 3b, 3c and 4 shares was extended from 7 to 10 years.
8. Tranches 11a, 11b and 11c were forfeited and have been cancelled on 5 August 2022.
9. Tranches 1a, 2a and 3a were forfeited and have been cancelled on 18 July 2025.

**Fair values of share-based payments**

***Loan Share Plan***

The fair value of all loan shares granted to Directors, other key management personnel, other employees and consultants have been calculated using an industry standard option pricing model. Where relevant, the expected life used in the model has been adjusted based on management's best estimate for the effects of non-transferability, exercise (including the probability of meeting market conditions attached to the option), and behavioural considerations. The model requires the Company share price volatility to be measured. The share price volatility has been measured with reference to the historical share prices of the Company and other similar Companies.

The fair value of share-based payments is calculated on the date of issue less any consideration paid.

Following the consolidation of the Company's equity in September 2017, all share numbers and prices are reported on a post consolidation basis.

Details in respect of the fair value of equity, on issue/grant date, that was in existence at reporting date are outlined below.

| Equity Instrument | Loan /Exercise price $ | Share price on issue Date $ | Volatility | Initiate Maturity date | Time to maturity | Risk free interest rate | Expected dividend yield |
|---|---|---|---|---|---|---|---|
| Tranche 1 | 0.05 | 0.05 | 74% | 29/06/2022 | 7 years | 2.61% | - |
| Tranche 2 | 0.05 | 0.05 | 74% | 30/06/2023 | 7 years | 1.81% | - |
| Tranche 3 | 0.092 | 0.092 | 74% | 11/05/2024 | 7 years | 2.39% | - |
| Tranche 4 | 0.14 | 0.14 | 74% | 26/07/2024 | 7 years | 2.46% | - |
| Tranche 5 | 0.20 | 0.20 | 74% | 04/12/2024 | 7 years | 2.36% | - |
| Tranche 10 | 0.15 | 0.15 | 77.4% | 01/11/2026 | 7 years | 0.98% | - |
| Tranche 13 | 0.134 | 0.134 | 91.9% | 30/07/2027 | 7 years | 0.65% | - |

Share Tranches 6, 9, 11 and 12 were issued for nominal consideration and valued at the 5-day VWAP on the day of issue.

For personal use only

***Options***

During the reporting period the Company issued 3,050,612 options to a corporate advisor for capital raising services. The amount recognised for the financial period under the share-based payment reserve amounted to $24,710. All options issued during the period have vested.

The fair value of options at grant date is determined using generally accepted valuation techniques that take into account exercise price, the term of the option, the impact of dilution, the share price at grant date, the expected price volatility of the underlying share, the expected dividend yield and the risk-free rate for the term of the option and an appropriate probability weighting to factor the likelihood of the satisfaction of non-vesting conditions. The expected volatility is based on historic volatility, adjusted for any expected changes to future volatility due to publicly available information.

Inputs used to value the share options are as follows:

| | Tranche 1 | Tranche 2 |
|---|---|---|
| Number of options | 1,525,306 | 1,525,306 |
| Grant date | 18-Jul-2025 | 18-Jul-2025 |
| Expiry date | 15-May-2028 | 15-May-2030 |
| Share price at grant date | $0.018 | $0.018 |
| Exercise price | $0.034 | $0.046 |
| Expected volatility | 85% | 85% |
| Risk-free interest rate | 3.37% | 3.61% |
| Model used | Black-scholes | Black-scholes |
| Value per option | $0.0071 | $0.0091 |

For personal use only

## Note 14: Reserves and accumulated losses

| | Note | 2026 | 2025 |
|---|---|---|---|
| | | $ | $ |
| Share options reserve | (a) | 24,710 | - |
| Share loan plan reserve | (b) | 550,758 | 712,090 |
| **Total reserves** | | **575,468** | **712,090** |

| (a) Share option reserve | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| Opening balance 1 July | - | 194,947 |
| Value of options issued | 24,710 | - |
| Cancellation of unlisted options lapsed during the period | - | (194,947) |
| **Closing balance** | **24,710** | **-** |

| (b) Share loan plan reserve | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| Opening balance 1 July | 712,089 | 712,089 |
| Value of shares recognised over vesting period[(a)] | - | - |
| Re-allocation of value of shares issued under the LSP which became unrestricted or cancelled during the period[(b)] | (161,332) | - |
| **Closing balance** | **550,757** | **712,089** |

(a) The equity settled reserves arise on issue of equity under the LSP or the issue of options
(b) Amounts are transferred out of the reserves and into issued capital when the loans are repaid, shares issued for nominal value vest or the options are exercised. Amounts are transferred to accumulated losses when the shares or options are cancelled.

| (c) Movement in accumulated losses | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| Opening balance 1 July | (22,029,940) | (19,640,419) |
| Re-allocation of value of options lapsed during the period | 161,332 | 194,947 |
| Net loss for the year | (2,330,805) | (2,584,468) |
| **Closing balance** | **(24,199,413)** | **(22,029,940)** |

## Note 15: Cash flow Information

| (a) Reconciliation of cash | 2026 | 2025 |
|---|---|---|
| | $ | $ |
| Cash at bank | 388,268 | 79,327 |
| Deposit at call | 1,551,322 | 559,011 |
| Term deposits | - | 500,000 |
| **Total cash and cash equivalents** | **1,939,590** | **1,138,338** |

### (b) Reconciliation of cash used in operating activities with loss after income tax

| | | |
|---|---|---|
| **Loss from continuing operations after income tax** | (2,330,805) | (2,584,468) |
| **Non cash movements:** | | |
| Depreciation and amortisation expense | 42,003 | 41,928 |
| Unrealised foreign exchange | 3,118 | - |
| **Changes in assets and liabilities:** | | |
| (Increase)/decrease in trade and other receivables | 64,785 | 28,251 |
| (Increase)/decrease in other current assets | 234,204 | (155,765) |
| Increase/(decrease) in trade creditors and accruals | 47,990 | 127,286 |
| **Cash used in operating activities** | **(1,938,705)** | **(2,542,768)** |

## Note 16: Commitments and contingencies

### (a) Capital expenditure commitments

Committed but unrecognised capital expenditure as at reporting date amounted to $Nil (2025: $Nil).

### (b) Other contingencies

#### Research and development incentive

Research and Development grants received may be subject to review by AusIndustry and subsequent claw back of funds should there be a determination of non-conforming claims.

#### Research and development commitments

As at the date of this report two major toxicological studies (OECD 443/OECD 417) were progressing with two separate overseas contract research organisations with a further $625,000 committed in study fees. This will be paid in instalments on completion of experimentation work and finalisations of reports prior to the end of FY2027.

## Note 17: Financial instruments

### (a) Capital risk management

The Company manages its capital to ensure that it will be able to continue as a going concern while maximising the return to stakeholders through the optimisation of the debt and equity balance. The Company's overall strategy remains unchanged from the prior financial year.

The capital structure of the Company consists of cash and cash equivalents and equity attributable to equity holders, comprising issued capital, reserves and retained earnings as disclosed in Notes 13 and 14 respectively. The Company operates globally, primarily through arrangements with suppliers established in the markets in which the Company trades.

Operating cash flows are used to maintain and expand the Company's assets.

For personal use only

For personal use only

### Gearing ratio

The Company's Board reviews the capital structure on a half-yearly basis. As a part of this review the Board considers the cost of capital and the risks associated with each class of capital. The Company has a target gearing of 0% in line with the industry norm that is determined as the proportion of net debt to equity. Based on recommendations of the Board the Company will balance its overall capital structure through new share issues.

The gearing ratio at year end was as follows:

| | Note | 2026 $ | 2025 $ |
|---|---|---|---|
| **Financial assets at amortised cost** | | | |
| Debt (i) | | - | - |
| Cash and cash equivalents | 5 | 1,939,590 | 1,138,338 |
| **Net cash/(debt)** | | **1,939,590** | **1,138,338** |
| | | | |
| Equity (ii) | 13,14 | 2,090,495 | 1,627,016 |
| Net debt to equity ratio | | - | - |

(i) Debt is defined as long-term and short-term borrowings.

(ii) Equity includes all capital and reserves as detailed in Note 13 and 14.

### Financial risk management objectives

The Company's CFO monitors and manages the financial risks relating to the operations of the Company through internal risk reports which analyse exposures by degree and magnitude of risks. These risks include market risk (including currency risk, fair value interest rate risk and price risk), credit risk and liquidity risk. There have been no changes to these risks since the previous financial year.

The Board of Directors ensures that the Company maintains a competent management structure capable of defining, analysing, measuring and reporting on the effective control of risk inherent in the Company's underlying financial activities and the instruments used to manage risk. Key financial risks including interest rate risk and foreign currency risk are reviewed by management on a regular basis and are communicated to the Board so that it can evaluate and impose its oversight responsibility. The Company does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes. The Company currently does not hedge foreign exchange exposure however each transaction is assessed on a case-by-case basis. This and other financial risks are managed prudently by the Chief Financial Officer and the Board.

**The entity holds the following financial instruments:**

| | Note | 2026 | 2025 |
|---|---|---|---|
| | - | $ | $ |
| **Financial assets at amortised cost** | | | |
| Cash and cash equivalents | 5 | 1,939,590 | 1,138,338 |
| Trade and other receivables | 6 | 407,639 | 472,424 |
| Other current assets | 7 | 125,440 | 359,644 |
| | | **2,472,669** | **1,970,406** |
| **Financial liabilities at amortised cost** | | | |
| Trade and other payables | 10 | 354,492 | 310,463 |
| Financial liabilities | 12 | - | 51,209 |
| | | **354,492** | **361,672** |

### (b) Market risk

The Company's activities expose it primarily to the financial risks of changes in foreign currency rates. The Company undertakes a number of its research activities overseas, as the necessary experience and facilities are not available in Australia, and as such has exposure to foreign currency movements which are predominately in US dollars. The Board and Chief Financial Officer monitor the potential impact of movements in foreign exchange exposure. The Company currently does not hedge foreign exchange exposure however each transaction is assessed on a case-by-case basis.

### (c) Interest rate risk management

The Company's exposure to market interest rates relates primarily to the Company's short-term deposits held and deposits at call. The interest income earned from these balances can vary due to interest rate changes.

The sensitivity analysis below has been determined based on the exposure to interest rates for both derivatives and non-derivative instruments at the end on the reporting period. If interest rates had been 100% higher/lower and all other variables were held constant, the Company's loss for the year ended 30 June 2026 would increase/decrease by $24,908 (2025: $39,438) (Note 3(a)).

### (d) Liquidity risk

Liquidity risk is the risk that the Company will not be able to pay its debts as and when they fall due. The Company has no borrowings at reporting date and the Directors ensure that the cash on hand is sufficient to meet the commitments of the Company at all times during the research and development phase.

The Company manages liquidity risk by monitoring forecast cash flows and ensuring that adequate cash and where necessary unutilised borrowing facilities are maintained.

## Financing arrangements

The Company does not have access to any borrowing facilities at the reporting date.

For personal use only

For personal use only

## Maturities of financial liabilities

The tables below analyse the Company's financial liabilities.

| 30 June 2026 | 0 -12 months | Maturing 1 to 3 years | Total |
|---|---|---|---|
| Financial Liabilities at amortised cost | | | |
| Trade and other payables | 354,492 | - | 354,492 |
| Financial liabilities | - | - | - |
| | **354,492** | **-** | **354,492** |

| 30 June 2025 | 0 -12 months | Maturing 1 to 3 years | Total |
|---|---|---|---|
| Financial Liabilities at amortised cost | | | |
| Trade and other payables | 310,463 | - | 310,463 |
| Financial liabilities | 51,209 | - | 51,209 |
| | **361,672** | **-** | **361,672** |

All current balances mature within one year; all non-current balances are expected to mature in between one and three years.

### (e) Foreign currency risk management

The Company undertakes certain transactions denominated in foreign currencies, hence exposures to exchange rate fluctuation arise. Exchange rate exposures are managed within approved policy parameters. The Company manages the currency risk by monitoring the trend of the US dollar, the Euro and Pound Sterling.

The entity's foreign currency risk denominated financial assets and financial liabilities at the reporting date are as follows:

| | 30 June 2026 | | | 30 June 2025 | | |
|---|---|---|---|---|---|---|
| | USD | EUR | GBP | USD | EUR | GBP |
| **Financial Assets at amortised cost** | | | | | | |
| Cash and cash equivalents | - | - | - | - | - | - |
| Trade and other receivables | - | - | - | - | - | - |
| **Financial Liabilities at amortised cost** | | | | | | |
| Trade and other payables | 41,500 | - | 680 | 8,500 | 784 | 1,650 |

The following sensitivity analysis is based on the foreign currency risk exposures in existence at the statement of financial position date. A 10 percent increase or decrease in the foreign exchange rate is used and represents management's assessment of the possible change in foreign exchange rates and historically is within a range of rate movements. A positive number indicates an increase in result and other equity. A negative number indicates a decrease in result and other equity. At 30 June 2026, if foreign exchange rates had moved, as illustrated in the table below, with all other variables held constant, pre-tax result and equity would have been affected as follows:

| | -10% in AUD | | +10% in AUD | |
|---|---|---|---|---|
| | Profit | Equity | Profit | Equity |
| | $ | $ | $ | $ |
| **30 June 2026** | | | | |
| **Financial Assets at amortised cost** | | | | |
| Cash and cash equivalents | - | - | - | - |
| Trade and other receivables | - | - | - | - |
| | - | - | - | - |
| **Financial Liabilities at amortised cost** | | | | |
| Trade and other payables | (7,266) | (7,266) | 5,945 | 5,945 |
| Financial liabilities | - | - | - | - |
| | **(7,266)** | **(7,266)** | **5,945** | **5,945** |
| **30 June 2025** | | | | |
| **Financial Assets at amortised cost** | | | | |
| Cash and cash equivalents | - | - | - | - |
| Trade and other receivables | - | - | - | - |
| | - | - | - | - |
| **Financial Liabilities at amortised cost** | | | | |
| Trade and other payables | (1,976) | (1,976) | 1,617 | 1,617 |
| Financial liabilities | - | - | - | - |
| | **(1,976)** | **(1,976)** | **1,617** | **1,617** |

### (f) Price risk

Price risk is the risk that future cashflows derived from financial instruments will be changed as a result of a market price movement, other than foreign currency rates and interest rates. The Company is not exposed to any material commodity price risks, other than those already described above.

## Net fair values

The carrying amount of financial assets and financial liabilities recorded in the financial statements approximates their net fair values.

The net fair values of financial assets and financial liabilities are determined as follows:

- the net fair value of financial assets and financial liabilities with standard terms and conditions and traded on active liquid markets are determined with reference to quoted market prices; and
- the net fair value of other financial assets and financial liabilities are determined in accordance with generally accepted pricing models based on discounted cash flow theory.

### (g) Credit risk management

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Company. The Company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate as a means of mitigating the risk of financial loss from defaults.

In addition, receivable balances are monitored on an ongoing basis with the result that the Company's exposure to bad debts is not significant. There are no significant concentrations of credit risk within the Company.

For personal use only

For personal use only

## Note 18: Key management personnel

### (a) Details of key management personnel

The Directors and other members of key management personnel of the Company during the year were:

| Name | Position |
|---|---|
| Mr. Alex Ding | Non-Executive Chair |
| Mr. Andrew Guthrie | Non-Executive Director |
| Mr. Chris Ramsey | Non-Executive Director |
| Mr. Tim Grogan | Managing Director and Chief Executive Officer |
| Mr. Peter May | Executive Director – Research and Development |
| Mr. Drew Speedy | Chief Financial Officer and Company Secretary (appointed 1 Feb 2026) |
| Mr. Edmond Tern | Chief Financial Officer and Company Secretary (resigned 1 Feb 2026) |

### (b) Key management personnel compensation

The aggregate compensation made to Directors and other members of key management personnel of the Company is set out below:

| | 2026<br>$ | 2025<br>$ |
|---|---|---|
| Short term employee benefits | 824,202 | 874,097 |
| Post-employment benefits | 88,795 | 100,635 |
| Equity based payments | - | - |
| | **912,997** | **974,732** |

Further disclosures regarding key management personnel compensation are contained within the Remuneration Report.

## Note 19: Related party transactions

### (a) Receivable from and payable to related parties

The following balances were outstanding at 30 June 2026 in relation to transactions with related parties:

| | 2026<br>$ | 2025<br>$ |
|---|---|---|
| **Current payables** | | |
| Trade payables to directors or their related entities | - | - |

There were no other loans to or from related parties at the current and previous reporting date. All transactions were made on normal commercial terms and conditions and at market rates.

For personal use only

### (b) Transactions with key management personnel

Details of key management personnel compensation are disclosed in Note 18 and the Remuneration Report.

## Note 20: Segment information

A segment is a component of the Company that engages in business activities to provide products or services within a particular economic environment. The Company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides. The Board of Directors assess the operating performance of the Company based on management reports that are prepared on this basis. The Company invests excess funds in short term deposits but this is not regarded as being a separate segment.

Two development programs funded under the United States Department of Defense's Deployed Warfighter Protection program are supported by approximately A$3.0 million in competitive grant funding over three years. Research grants of $584,478 were recognised in FY26, constituting 54% of total other income ($1,078,888).

## Note 21: Income Tax

| Income tax reconciliation: | 2026<br>$ | 2025<br>$ |
|---|---|---|
| Profit/(Loss) before tax | (2,230,804) | (2,584,468) |
| Prima-facie income tax to tax expense at the rate of 25% (2025: 25%) | (557,701) | (646,117) |
| **Add:** | | |
| ***Tax effect of:*** | | |
| R&D expenditure not deductible | 229,885 | 298,565 |
| Other non-deductible expenses | (860) | 52,655 |
| Tax losses deferred | 408,329 | 477,734 |
| **Less:** | | |
| ***Tax effect of:*** | | |
| R&D incentive not assessable | (142,376) | (96,409) |
| Timing differences not recognised | 62,722 | (86,428) |
| | - | - |

## Note 22: Events occurring after the reporting period

On 5 August 2026, the Company held a Shareholders meeting to consider key resolutions including:

- Issue of placement shares to related parties
- Issue of SPP shortfall shares as per the SPP Underwriting Agreement
- Issue of unlisted options tied to placement shares, Share Purchase Plan (SPP) shares, SPP Underwriting and the lead manager for a recent capital raise

All resolutions were passed with >96% shareholder approval, reflecting strong investor support.

On 10 August 2026, the Company issued the following securities in relation to the Capital raising activities:

- 34,760,000 fully paid ordinary shares, raising A$869,000 (before costs) in relation to Tranche 2 of the placement;
- 15,220,000 fully paid ordinary shares, raising A$380,500 (before costs) in relation to the SPP Underwriting Agreement;
- 2,000,000 fully paid shares to an Advisor to the capital raising activities in relation to services provided.; and
- 69,221,150 options exercisable at 3.5 cents per option expiring on 15 October 2027.


For personal use only

## DECLARATION BY DIRECTORS
## FOR THE YEAR ENDED 30 JUNE 2026

The directors of the company declare that:

- The financial statements and notes, as set out in the following pages, are in accordance with the *Corporations Act 2001:*
    - comply with applicable Accounting Standards and the *Corporations Regulations 2001*; and
    - give a true and fair view of the financial position as at 30 June 2026 and of the performance for the year ended on that date.
- In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.
- The directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the *Corporations Act 2001.*

This declaration is made in accordance with a resolution of the board of directors.



**Mr. Alex Ding**

Director

Date: 28 August 2026

For personal use only

Horizon Nexus Partners

Horizon Nexus (Audit) Pty Ltd (ABN 33 692 918 577)
Level 4, 35 Collins Street, Melbourne, Victoria, 3000
PO Box 24155, Melbourne, Victoria 3001
horizonnp.com.au

**BIO-GENE TECHNOLOGY LIMITED**

**ABN 32 071 735 950**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF BIO-GENE TECHNOLOGY LIMITED**

**Report on the Audit of the Financial Report**

**Opinion**

We have audited the financial report of Bio-Gene Technology Limited (the Company), which comprises the statement of financial position as at 30 June 2026, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, the Consolidated Entity Disclosure Statement and the directors' declaration.

In our opinion, the accompanying financial report of Bio-Gene Technology Limited, is in accordance with the *Corporations Act 2001*, including:

a) giving a true and fair view of the Company's financial position as at 30 June 2026 and of its financial performance for the year then ended; and
b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

**Basis for Opinion**

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) issued by the Accounting Professional & Ethical Standards Board Limited that are relevant to audits of the financial report of public interest entities in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Material Uncertainty Related to Going Concern**

We draw your attention to Note 1(a) (Going Concern) in the financial report, which indicates the Company incurred an operating loss of $2,330,805 (2025: $2,584,468) and a negative cash outflow from operating activities of $1,938,705 (2025: $2,542,768).

As stated in Note 1(a), these events or conditions, along with other matters as set forth in Note 1(a), indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

For personal use only



Liability limited by a scheme approved under Professional Standards Legislation.

For personal use only

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

| R&D Tax Incentive | |
|---|---|
| Refer also to Note 1 (Accounting Policy), Note 3 (Financial Disclosures) | We focused on the R&D tax incentive due to the material nature of the receivable and because there is a degree of judgement and interpretation of the R&D tax legislation required in assessing the eligibility of the R&D expenditure under the scheme. There is an inherent level of subjectivity in the R&D incentive in regard to the level of receivable recognised and the recognition of the related income.<br><br>Our audit procedures included:<br>• Discussion with management to determine an understanding of the R&D environment the business operates in and to understand the process used to estimate the R&D tax incentive.<br>• Comparing the estimates recorded as a receivable made in previous years to the amount of cash physically received after year end.<br>• Testing the mathematical accuracy of the calculation and agreeing inputs to supporting documentation.<br>• Reviewing the classification of expenses included in the R&D claim to ensure that they meet the criteria of R&D expenditure.<br>• Assessing the adequacy of the related disclosures within the financial statements and reviewing the accounting treatment in line with Australian Accounting Standards. |

For personal use only

| Share Options & Equity Transactions | |
|---|---|
| Refer also to Note 1 (Accounting Policy), Note 13 (Financial Disclosures) | The Company issued shares to executive directors and senior management under a share-based compensation plan. These arrangements have differing terms and conditions that give rise to different accounting outcomes.<br><br>Share based payment arrangements require judgemental assumptions including volatility rates and expected life in determining the fair value of the arrangements and the expensing of that fair value over the estimated service period.<br><br>Our audit procedures included:<br>• We assessed the terms of the share-based payment arrangements issued during the period including review of documentation issued to shareholders.<br>• We assessed the methodology used by the Company in valuing the share options.<br>• We assessed the expense recorded on the statement of comprehensive income.<br>• We assessed the share capital recorded for any loan repayments.<br>• Assessing the adequacy of the related disclosures within the financial statements and reviewing the accounting treatment in line with Australian Accounting Standards. |

**Other Information**

The directors are responsible for the other information. The other information comprises the information included in the Company's annual report for the year ended 30 June 2026 but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of the Directors for the Financial Report**

The Directors of the Company are responsible for the preparation of:

a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and *the Corporations Act 2001*; and

b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and for such internal control as the directors determine is necessary to enable the preparation of:

   i. the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and

   ii. the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or has no realistic alternative but to do so.

**Auditor's Responsibilities for the Audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going

For personal use only

concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation. We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters.

We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**Report on the Remuneration Report**

**Opinion on the Remuneration Report**

We have audited the Remuneration Report included in Pages 19 to 27 of the directors' report for the year ended 30 June 2026.

In our opinion, the Remuneration Report of Bio-Gene Technology Limited, for the year ended 30 June 2026, complies with section 300A of the *Corporations Act 2001*.

**Responsibilities**

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Horizon Nexus (Audit) Pty Ltd

**Horizon Nexus (Audit) Pty Ltd**

**Sam Claringbold**

**Melbourne, Victoria**

**Date:** 28th August 2026

For personal use only

# SHAREHOLDER INFORMATION

## A. Substantial shareholders

Holders of Relevant Interests as notified by ASX Substantial Shareholders under Part 6.7 of the *Corporations Act 2001* as at 20 August 2026.

| Holder | Ordinary Shares (i) | % of Total issued Capital |
|---|---|---|
| DR CHOON LEE | 58,011,245 | 13.24% |
| VANA BELLE PTY LTD | 34,122,081 | 7.79% |
| MARK CHANG | 29,109,174 | 6.65% |

## B. Number of holders of equity securities and voting rights

| | Ordinary Shares (i) | Share Options (ii) |
|---|---|---|
| Number of shareholders as at 20 August 2026 | 1,095 | 162 |

The voting rights attaching to each class of equity securities are:

**(i) Ordinary shares**

On a show of hands, every member present at a meeting, in person or by proxy, shall have one vote and upon a poll each share shall have one vote.

**(ii) Options**

No voting rights.

## C. Distribution of equity securities

Distribution of shareholders of equity securities as at 20 August 2026:

| No. of shareholders | Ordinary Shares | Options |
|---|---|---|
| 1 - 1,000 | 36 | - |
| 1,001 - 5,000 | 112 | - |
| 5,001 - 10,000 | 115 | - |
| 10,001 - 100,000 | 519 | 58 |
| 100,001 and over | 313 | 102 |
| | **1,095** | **160** |
| **Number of shareholders of less than a marketable parcel of shares** | **474** | |

For personal use only

### D. 20 largest shareholders of quoted securities

The names of the 20 largest shareholders of each class of quoted equity securities as at 20 August 2026 are listed below:

| No. | Shareholder Name | 20 August 2026 | % IC |
|---|---|---|---|
| 1 | DR CHOON HUAT LEE | 38,956,212 | 8.89% |
| 2 | VANA BELLE PTY LTD | 33,501,034 | 7.65% |
| 3 | CITICORP NOMINEES | 19,938,322 | 4.55% |
| 4 | ALINA BARLOW | 18,995,859 | 4.34% |
| 5 | BACTENCE PTY LTD | 16,674,081 | 3.81% |
| 6 | BNP PARIBAS NOMINEES PTY LTD | 13,165,400 | 3.01% |
| 7 | JAMES CHESTER | 11,873,028 | 2.71% |
| 8 | BINVID PTY LTD | 10,000,000 | 2.28% |
| 9 | SOMMERS SUPER PTY LTD | 8,050,000 | 1.84% |
| 10 | MORGAN STANLEY AUSTRALIA SECURITIES (NOMINEE) PTY LIMITED | 8,000,000 | 1.83% |
| 11 | CHANG MUN KEE | 8,000,000 | 1.83% |
| 12 | BNP PARIBAS NOMINEES PTY LTD | 5,436,957 | 1.24% |
| 13 | MR MARK WINFIELD & MRS LYNETTE WINFIELD | 5,349,495 | 1.22% |
| 14 | T & L AINSWORTH INVESTMENTS PTY LTD | 4,683,185 | 1.07% |
| 15 | RUMBLE NOMINEES PTY LTD | 4,598,913 | 1.05% |
| 16 | PENN NOMINEES PTY LTD | 4,000,000 | 0.91% |
| 17 | GEEAI INVESTMENTS PTY LIMITED | 4,000,000 | 0.91% |
| 18 | PARNCUTT FAMILY FOUNDATION PTY LTD | 4,000,000 | 0.91% |
| 19 | INVIA CUSTODIAN PTY LIMITED | 4,000,000 | 0.91% |
| 20 | MR SEBASTIAN ANDREW MARR | 4,000,000 | 0.91% |
| | **Total 20** | **227,222,486** | 51.87% |
| | **Total Issued Capital** | **438,061,108** | 100.00% |

For personal use only

### E. Shares subject to restriction arrangements

The total number of shares subject to restriction arrangements is 9,380,902 shares. These shares were all issued under the Loan Share Plan and the escrow period ends on the latter of the date of repayment of the associated loan or as outlined below:

| Date shares issued | Vesting date | Expiry date | Number of shares |
|---|---|---|---|
| 30/06/2016 | 30/06/2016 | 30/06/2026 | 96,000 |
| 11/05/2017 | 11/11/2017 | 11/05/2027 | 312,500 |
| 11/05/2017 | 11/05/2018 | 11/05/2027 | 812,500 |
| 26/07/2017 | 26/01/2018 | 26/07/2027 | 187,500 |
| 26/07/2017 | 26/07/2018 | 26/07/2027 | 187,500 |
| 04/12/2017 | 04/06/2018 | 04/12/2025 | 500,000 |
| 04/12/2017 | 04/12/2018 | 04/12/2025 | 500,000 |
| 01/11/2019 | 30/06/2022 | 01/11/2026 | 2,201,972 |
| 30/07/2020 | 30/06/2024 | 30/07/2027 | 1,262,930 |
| | | | **6,060,902** |

For personal use only

# COMPANY PARTICULARS

**Directors**

Alex Ding
Andrew Guthrie
Chris Ramsey
Tim Grogan
Peter May

**Auditors**

Horizon Nexus Partners
Level 4
35 Collins Street
Melbourne, VIC 3000

**Secretary**

Drew Speedy

**Lawyers**

Quinert Rodda & Associates Pty Ltd
Level 6
400 Collins Street
Melbourne, VIC 3000

**Australian Company Number**
071 735 950

**Australian Business Number**
32 071 735 950

**Media & Investor Relations**

NWR Communications Pty Ltd
Level 6, 350 Collins Street Melbourne VIC 3000


Matt Wright
E: matt.wright@nwrcommunications.com.au

**Registered Office**
Level 6
400 Collins Street
Melbourne, VIC 3000
Contact E-Mail
Email: bgt.info@bio-gene.com.au
Website: www.bio-gene.com.au

**Share Registry**
Automic Pty Ltd
Level 5
126 Phillip Street
Sydney, NSW 2000

Flavocide® and Qcide®
are trademarks of Bio-Gene Technology Limited

Securities Quoted
Australian Securities Exchange (ASX)
Ordinary Fully Paid Shares (Code: BGT)



For personal use only